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1. Summary 
 
Surgery for the treatment of liver tumors relies on the unique ability of liver to regenerate 
after tissue loss. Although surgery is the most curative treatment for extensive tumor loads, 
limitations to the extent of resections exist, with resection-induced liver failure (known as 
small-for-size syndrome, SFSS) remaining the primary cause of postoperative death. 
Therefore, there is a need for innovative approaches to push the boundaries of resection in 
liver surgery.  
ALPPS - Associated Liver Partition and Portal vein ligation for Staged hepatectomy - is 
the most recent advancement in the treatment of extensive liver tumors. ALPPS is a modified 
two-staged hepatectomy that allows for a more extensive tumor removal than usual 
approaches. In conventional two-stage hepatectomies, the diseased liver part is occluded in 
the first stage to induce growth of the contralateral healthy liver part, enabling the resection of 
the diseased part at the second stage. Unlike in conventional approaches, ALPPS combines 
occlusion with parenchymal transection, which induces liver regeneration at an unprecedented 
rate. In patients, ALPPS stage 1 enables resection (i.e. stage 2) in just ten days compared to 2-
13 months after conventional two-staged hepatectomies, while in mice, regeneration doubles 
or triples in speed. The molecular pathways behind this accelerated regeneration remain 
uncharacterized. The aim of my PhD thesis was to explore unique molecular mechanisms 
underlying the accelerated regeneration induced by ALPPS surgery. 
RNA deep sequencing on ALPPS regenerative tissue revealed unique gene expression 
changes as early as 4 hours after operation. Further analyses identified Indian hedgehog (IHH) 
as a primary candidate in mediating ALPPS regeneration. Through functional in-vivo assays, 
the necessity of IHH in accelerated regeneration was confirmed. When recombinant IHH 
protein was injected into the slower regenerating PVL (portal vein ligation only) mice, 
regeneration was accelerated to ALPPS levels. On the contrary, neutralizing IHH antibody 
injected prior to ALPPS surgery slowed regenerative speed to levels seen in PVL only mice. 
Furthermore, ALPPS induced IHH secretion from stellate cells, which led to paracrine 
activation of the hedgehog effector GLI1 and its target cyclin D1 in hepatocytes accompanied 
by increases in hepatocellular proliferation. All these events were replicated by recombinant 
IHH injected into PVL mice, and abrogated in ALPPS mice by neutralizing IHH antibody. 
To establish the important of IHH in ALPPS, IHH upstream regulators were explored 
through in-silico mining of transcriptomics data, which identified Mapk8 (JNK1) as a 
potential candidate. JNK1 activation was validated at the protein level to occur 1 hour after 
ALPPS surgery (preceding IHH secretion at 4 hours). Immunofluorescence indicated JNK1-
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IHH co-localization in stellate cells. Pharmacological inhibition of JNK1 through SP600125 
prior to ALPPS surgery reduced the regenerative pace to PVL levels, abrogated IHH 
secretion, counteracted the subsequent induction of GLI1-cyclin D in hepatocytes, and 
reduced hepatocellular proliferation. When recombinant IHH was injected into ALPPS mice 
with inhibited JNK1, GLI1-cyclin D upregulation was restored, as was hepatocellular 
proliferation and accelerated regeneration. Intriguingly, recombinant IHH also re-elevated 
JNK1 activity, suggesting a feed forward loop, which to establish will require further 
research.  
 Finally, a proteomics approach was used to investigate additional plasma proteins that 
may trigger acceleration of regeneration after ALPPS. Previous experiments with plasma 
injections indicated the presence of accelerating proteins present in circulation as early as 30 
minutes after surgery. While several candidates were detected through proteomics, their 
validation proved difficult. Nevertheless, novel plasma proteins displaying unique 
upregulation after ALPPS were identified, however without a clear association with the 
JNK1-IHH axis but feeding future research. 
In conclusion, the experimental work for my PhD thesis has identified the first molecular 
mechanism that drives the acceleration of regeneration after ALPPS surgery. ALPPS triggers 
early activation of JNK1 in stellate cells to promote subsequent release of IHH, which then 
accelerates hepatocyte proliferation via GLI1-cyclinD in a paracrine fashion. Mechanistically, 
regenerative acceleration may result from a positive feedback between IHH and JNK1. If 
confirmed in patients, the JNK1-IHH-GLI1-cyclin D axis may be therapeutically exploited for 
patients at risk of SFSS, a currently untreatable entity.  
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2. Zusammenfassung 
 
Die chirurgische Enfernung von Lebertumoren beruht auf der einzigartigen Fähigkeit der 
Leber, sich nach Gewebeverlust vollständig zu regenerieren. Obwohl die Chirurgie die 
erfolgreichste Option bei starkem Tumorbefall darstellt, sind ihr Grenzen gesetzt. Wird zu 
viel Lebergewebe entfernt, kann Leberversagen eintreten. Dieses sogenannte 'Small-For-Size 
Syndrom' (SFSS) ist nach wie vor die häufigste postoperative Todesursache in der 
Leberchirurgie. Deshalb besteht der Bedarf nach innovativen Ansätzen, welche die Grenzen 
der Resektibilät weiter ausdehnen. 
ALPPS - 'Associated Liver Partition and Portal vein ligation for Staged hepatectomy' - ist 
eine Abwandlung sogenannter 2-Stufen-Resektionen und die neueste chirurgische Strategie 
zur extensiven Entfernung von grossen oder multiplen Lebertumoren. Bei 2-Stufen-
Resektionen wird im ersten Schritt der erkrankte Leberteil ligiert ('portal vein ligation', PVL), 
um kompensierendes Wachstum im gesunden Leberteil zu induzieren. Wenn dieser genügend 
gewachsen ist, kann in einem zweiten Schritt der kranke Leberteil reseziert werden. Im 
Gegensatz zu den üblichen 2-Stufen-Resektionen, wird bei ALPPS die Schritt 1-Ligation 
zusätzlich mit einer parenchymalen Transektion kombiniert, was das Wachstum des gesunden 
Leberteiles massiv beschleunigt. Dadurch kann die Resektion (Schritt 2) bereits nach etwa 10 
Tagen statt der üblichen 2-13 Monate durchgeführt werden, während die ALPPS Operation in 
Mäusen die Regenerationsrate um das zwei- bis dreifache beschleunigt. 
Die molekularen Prozesse, welche der ALPPS-induzierten Beschleunigung der 
Leberregeneration zugrunde liegen, sind noch ungeklärt. Das Ziel meiner Dissertation war, 
die für die regenerative Beschleunigung wesentlichen Signalwege zu identifizieren, um eine 
mechanistische Erklärung für das ALPPS-Phänomen zu ermöglichen.  
Mittels 'RNA deep sequencing' konnte ich 4 Stunden nach der Operation ALPPS-
spezifische Expressionsmuster beobachten. Weitere Analysen identifizierten Indian Hedgehog 
(IHH) als das primäre Kandidatenmolekül in der ALPPS Regeneration. Durch funktionelle in 
vivo Experimente konnte dir Rolle von IHH als Regenerationsbeschleuniger in ALPPS 
bestätigt werden. Wenn rekombinantes IHH nur mit PVL-behandelten (also langsam 
regenerierenden) Mäusen injiziert wurde, beschleunigte sich die Regeneration auf ALPPS 
Niveau. Umgekehrt, die Regeneration wurde auf PVL Niveau verlangsamt, wenn Mäusen vor 
der ALPPS Operation neutralisierender Antikörper gegen IHH verabreicht wurde. Weiter 
konnten wir zeigen, dass IHH von Sternzellen sekretiert wurde, um parakrin den hedgehog 
Effektor GLI1 und sein Zielgen cyclin D1 in Hepatozyten zu aktivieren und dadurch deren 
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Proliferation zu verstärken. All diese Effekte wurden durch rekombinantes IHH in PVL 
Mäusen repliziert, und durch neutralisierenden IHH Antikörper in ALPPS Mäusen 
unterbunden.  
Um die zentrale Rolle von IHH in ALPPS zu bestätigen, haben wir nach vorgelagerten 
IHH Regulatoren gesucht. Mittels in silico Analyse der Transkriptom Daten identifizierten 
wir Mapk8 (JNK1) als möglichen Kandidaten. Tatsächlich konnten wir eine Stunde nach 
ALPPS die Aktivierung der JNK1 Kinase bestätigen (also bevor IHH induziert wird) und 
weiter mittels Immunfluoreszenz feststellen, dass JNK1 mit IHH in Sternzellen ko-lokalisiert. 
Die pharmakologische Inhibierung der JNK1 vor der ALPPS Operation verlangsamte die 
Regenerationsgeschwindigkeit auf PVL Niveau, unterdrückte die IHH Sekretion sowie die 
Aktivierung von GLI1-cyclin D1 in Hepatozyten, und vermiderte die hepatozelluläre 
Proliferation. Wenn Mäusen mit inhibierter JNK1 vor der ALPPS Operation auch 
rekombinantes IHH injiziert wurde, wurde die GLI-cyclin D1 Induktion wiederhergestellt, die 
Heptozytenproliferation angekurbelt, und die Regeneration wieder beschleunigt. 
Interessanterweise konnte rekombinantes IHH auch die JNK1 Aktivität erhöhen, was auf eine 
wechselseitige Verstärkung zwischen diesen Proteinen hindeutet, aber eine Bestätigung in 
weiteren Studien erfordert.  
Schliesslich haben wir auch einen Proteomics Ansatz verfolgt, um zusätzliche 
Plasmaproteine, welche die Beschleunigung der ALPPS-Regeneration auslösen könnten, zu 
beschreiben. Vorgängige Experimente mit Plasmainjektionen wiesen auf die Präsenz von 
beschleunigenden Proteinen in der Zirkulation schon 30 min. nach der ALPPS Operation hin. 
Während mehrere Kandidaten durch Proteomics detektiert wurden, erwies sich deren 
Validierung im Plasma als schwierig. Nichtsdestotrotz, wir konnten neue Plasmaproteine mit 
spezifischer Aufregulierung durch ALPPS nachweisen - leider ohne eine Assoziation mit der 
JNK1-IHH Achse, dafür mit neuen Hinweisen für zukünftige Projekte.  
Zusammenfassend konnte ich in meiner Dissertation den ersten molekularen 
Mechanismus, welcher die ALPPS-induzierte Beschleunigung der Leberregeneration antreibt, 
identifizieren. ALPPS stimuliert die Aktivierung der JNK1 in Sternzellen, um die Sekretion 
des 'hedgehog' Liganden IHH zu fördern, welcher dann parakrin auf Hepatozyten wirkt, um 
dort mittels der GLI1-cyclin D1 Achse deren Proliferation zu beschleunigen. Die positive 
Wechselwirkung zwischen IHH und JNK1 könnte dabei eine mechanistische Erklärung für 
die Beschleunigung liefern. Falls diese Befunde im Patientenmaterial bestätigt werden, könnte 
die JNK1-IHH-GLI1-cyclin D1 Achse möglicherweise therapeutisch genutzt werden, um die 
Regeneration bei Patienten mit erhöhtem Risiko für das SFSS zu stimulieren.  
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3. Introduction 
 
3.1 The liver 
Triangular in shape, the liver is the largest gland in the body and accounts for about 
2.5% of the human body weight. The human liver is composed of four lobules and is 
anatomically located to serve its dual role as a metabolic and biochemical transformation 
factory [1]. Indeed, the liver is the central metabolic organ; accordingly, its functions are 
many but that can be divided into three categories: resorption and storage, synthesis and 
secretion, and detoxification and excretion [2]. The intricate architecture and cellular 
components of the liver complement and contribute to these varied functions.  
Liver architecture 
The hepatic lobule, the basic architectural unit of the liver, is composed of hepatocytes 
arranged in single-cell thick cords lined by sinusoidal capillaries that extend from the portal 
triad to the central vein. The liver receives 75% of its blood supply from the portal vein and 
the rest from the hepatic artery. The portal veins and hepatic arteries terminate in the 
intrahepatic portal tracts, which contain bile ducts that transport bile from the canaliculus 
through the extrahepatic biliary system. The terminal portal veins, or channels of Herring, 
give rise to septal branches that drain blood into the sinusoids that then take blood through the 
acinus to the central vein. The hepatic artery terminates in axial branches that run parallel to 
the portal vein and likewise terminate in sinusoids. Bile canaliculi are located on the lateral 
surfaces of adjoining hepatocytes (Fig 1). The blood from the portal triad is rich in oxygen 
(from the artery) and nutrients (from the portal vein, the terminal outflow of the mesenteric 
system), and as blood flows to the central vein, nutrients and oxygen are consumed creating 
three zones that differ in oxygenation and metabolic functions in the most metabolically 
relevant unit, the liver acinus [2]. Therefore, hepatocytes line up along the porto-central axis 
leading to a structural and functional heterogeneity known as metabolic zonation, allowing for 
maintenance of metabolic homeostasis in the body [1] and contributing to the varied vital 
functions of the liver.  
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Figure 1. (A) The physiology of the liver. Adapted from [1]. (B) Functional units of the liver 
parenchyma. Adapted from [2]. 
The parenchyma is composed of a network of cell plates made of hepatocytes that 
have di- or polyploid nuclei. The sinusoids are lined by highly specialized fenestrated 
endothelial cells characterized by the absence of tight junctions and lack of basement 
membrane. The sinusoidal endothelium is interspersed with Kupffer cells as well as the space 
of Disse, a specialized extracellular matrix containing stellate cells and occupying he space 
between LSECs and hepatocytes. Kupffer cells and NK cells may also bulge into the 
sinusoidal lumen [2,3] (Fig 2). Each cell type plays a specific role in maintaining liver 
homeostasis.  
   
 
 
 
 
 
Figure 2. The structural integration of hepatocytes and non-parenchymal cells in the liver. Adapted 
from [2]. 
 
Parenchymal and non-parenchymal cell types 
Hepatocytes are the most numerous cells in the liver (60-70% of all cells and 
composing 80% of its mass/volume) and are responsible for most of the synthetic and 
metabolic functions. To fulfill their numerous metabolic functions, hepatocytes contain a 
complex array of mitochondria, peroxisomes, lysosomes, Golgi complexes, rough and smooth 
endoplasmic reticulum, microtubules and microfilaments [1].  
(A) (B) 
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Nonparenchymal cells include endothelial cells, Kupffer cells, stellate cells, 
cholangiocytes, and natural killer cells. Endothelial cells, the second largest cell population 
(about 20% of all cells), form the lining of the sinusoidal wall and contain fenestrae. The 
endothelial cells form cylindrical structures in single cells in a row to form the typical liver 
capillary, the sinusoid. Free access of fluid, solutes, droplets, and particles from the lumen 
toward the space of Disse (and vice versa) occurs solely through the fenestrae. Hence, the 
fenestrated phenotype enables the blood-hepatocyte exchange and is a prerequisite for normal 
liver function. Kupffer cells, the macrophages of the liver, comprise about 2% of the liver 
volume/mass and are located within the lumen of sinusoids. Kupffer cells are phagocytic and 
when activated produce a large number of chemokines and cytokines for the liver’s acute 
phase response. Stellate cells comprise about 1.5% of the liver volume and are located in the 
space of Disse. They are multifunctional and metabolize vitamin A, synthesize, secrete, and 
degrade components of the perisinusoidal extracellular matrix. In response to cytokines, 
stellate cells acquire a myofibroblast phenotype, become migratory, and have a major role in 
the fibrotic response of the liver injury. Cholangiocytes, the only other type of epithelial cell, 
account for 3-5% of the liver cell population. Albeit small in population, they have an 
important pathophysiological role in the modification of the composition of bile during transit 
in the bile ducts. Cholangiocytes form the bile canaliculi and line the channels of Hering as 
bile flows to the periphery [4,5]. Lastly, liver-associated natural killer cells, or pit cells, are 
localized in the lumen of the sinusoid and closely adhere to the endothelial and Kupffer cells. 
They are important components of the liver-centered immune system involved in antigen 
presenting, removal, or neutralization of numerous foreign materials [1,6]. Therefore, the 
composition of the liver is varied albeit specific in its contribution to maintaining proper liver 
function. 
 
3.2 Liver regeneration 
 The Greek myth of Prometheus recalls an eagle devouring a titans liver during the day 
(a symbolic consumption of the physical manifestation of his soul), resulting in eternal torture 
for the titan as his liver regenerated back every night [7]. Today, we know that the liver is not 
necessarily the seat of the soul as the ancient Greeks believed, but rather an organ that 
provides a number of fundamental functions, such as detoxification and bodily provision of 
nutrients. Due to its diverse and vital functions, it is only reasonable that the liver is the only 
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organ in the body that is able to reach 100% re-adjustment to its original size after tissue loss 
or liver injury.  
In humans, up to 70% of the liver can be resected with a recovery of the original mass 
within 2-3 weeks [8]. The term ‘hepatostat’ has been coined to describe the livers ability to 
recover its original mass by proper initiation and termination of regeneration to recover its full 
functions after a massive loss of hepatocytes. However, only the mass and not the lobular 
composition of the liver is restored and therefore, ‘compensatory hyperplasia’ is a term most 
often used to describe regeneration. To be precise: first liver mass is reconstituted, followed 
by a long (i.e. several months) remodeling period that eventually restores the livers original 
architecture [9]. 
General concepts of liver regeneration 
 There are two models describing how the liver may regenerate: (i) replacement of 
tissue loss with phenotypic fidelity of cell types, or (ii) replacement of tissue by activation of 
transdifferentiation pathways originating from facultative stem cells [9]. These processes are 
not mutually exclusive and can occur at different proportions depending on the size of tissue 
loss and impairment of cellular compartments. Vaguely speaking, regeneration after partial 
hepatectomy occurs from the proliferation of differenitated hepatocytes, while regeneration 
after injury tends to be initiated from stem cells. To study these concepts of regeneration, 
various experimental animal models have been developed throughout the years; although we 
will focus on the standard model of regeneration after partial hepatectomy. 
 Higgins and Anderson first presented a murine standard hepatectomy model (sHx) in 
1931; whereby 70% of the liver is resected and liver regeneration mass is regained after 5-7 
days [8,10,11]. sHx has been established as a reliable model to study regeneration due to 
minimal liver injury, a synchronized cell cycle, and very high reproducibility. The lobular 
structure of murine livers allows the ‘clean’ removal of tissue without inducing massive 
necrosis. sHx stimulates quiescent G0 hepatocytes to enter the cell cycle, replicate their 
genome, undergo cytokinesis, and exit the cell cycle back to the resting state once the original 
liver mass has been restored [7]. At 32-48h after operation in mice, DNA synthesis peaks in 
hepatocytes, followed by initiation of DNA synthesis in nonparenchymal cells such as biliary 
epithelial cells, liver sinusoidal epithelial cells (LSECs), and stellate cells [1,12,13,14]. Liver 
regeneration may also be evaluated by models using chemicals to induce liver injury, such as 
CCl4 and APAP (acetyl-para-aminophenol; commonly known as acetaminophen); however, 
these regenerative responses differ in that they initiate from stem cells and are overlayed with 
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the pathogenesis of fibrosis and acute inflammation of necrotic zones [7,11,15]. Therefore, we 
will only focus on those mechanisms instigated by sHx. 
The phases of liver regeneration 
The kinetics of liver regeneration can be divided into three phases characterized by 
timely mechanisms, whereby hepatocytes are primed and prepared to enter the cell cycle 
(initiation) and then proceed through replication and mitosis (progression) to re-establish the 
original liver volume (termination). These processes are briefly described below and 
represented in Figure 3.  
Priming. It is a common belief that a cytokine-mediated priming process is essential for the 
quiescent hepatocytes to enter cell cycle during initiation of regeneration. Once primed, these 
hepatocytes respond to other mitogenic stimuli [9,16]. There is not a single signaling pathway 
associated with the complete success of the regenerative response, but based on the mode of 
action, extracellular signals are characterized as (i) complete mitogens and (ii) auxiliary 
mitogens [9]. HGF and EGF receptor ligands are complete mitogens as they are considered 
core drivers of parenchymal regeneration [1]. After sHx, HGF acts in an endocrine and 
paracrine manner on hepatocytes. The first round of HGF signaling is derived from the 
matrix, while stellate cells and endothelial cells produce new HGF after sHx. Although 
inactive HGF is available for use by hepatocytes already bound in the ECM, 3h after sHx 
stellate and endothelial cells start producing new HGF mRNA [17].   EGFR ligands that are 
important for survival after sHx are amphiregulatin and TGF-α that act in an autocrine manner 
on hepatocytes, as well as heparin-binding EGF-like growth factor (HB-EGF) synthesized by 
Kupffer cells and LSECs that acts in a paracrine manner. HB-EGF is also available from 
endothelial cells and macrophages [18]. Auxiliary mitogens include norepinephrine, Notch 
and Jagged, PDGF, VEGF, insulin, bile acids, serotonin, leptin, estrogens, triodothronine, 
TNF, FGF1 and FGF2 [1]. However, these classifications may remain somewhat artificial, as 
for example interruption of VEGF signaling can lead to a severe, long-lasting halt in 
regeneration [19]. Anyway, the combination of these signals results in hepatocyte cell cycle 
progression that leads to DNA synthesis and proliferation of hepatocytes. However, the liver 
employs effective redundancy to secure proper regeneration. Deregulation of either the HGF 
and EGF pathways delay the cell cycle by reducing G1 entry, and diminishing G1 to S phase 
and G2 to M phase transitions. Only depletion of both signaling pathways leads to complete 
failure of regeneration [20]. 
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Initiation. The immediate consequence of sHx is an increase in the entire flow of the portal 
vein to 1/3 of the remaining liver. Furthermore, several genes are initiated very shortly after 
sHx, also characterized as ‘immediate early genes’ (changes occurring within minutes to 
hours), that are thought to induce cells for cell cycle entry but are likewise induced in 
hypertrophic regeneration [21].  
The early mechanistic changes begin with a huge increase in the activity of urokinase 
within 5 minutes (perhaps activated through shear stress), followed by a cascade by which 
urokinase activates plasminogen into plasmin, and proceeds to activate metalloproteinases 
(MMPs). This protease cascade degrades specific components of the extracellular matrix 
(ECM) and is associated with the release of bound HGF. An early event is the nuclear 
translocation of -catenin, occurring as early as 5 min. after resection, followed by a peak at 
60 minutes, and continuous activity for at least 24 hours. LSECs are important inducers of -
catenin, as they provide mitogenic WNT2 to activate -catenin in the hepatocytes [19,22]. In 
the nucleus, -catenin dimerizes with TCF family transcription factors and initiates 
transcription of genes associated with the cell cycle. WNT, MET, and EGFR protect --
catenin by specific tyrosine phosphorylation to enhance its migration to the nucleus [9]. 
Furthermore, 15 minutes after sHx, Notch migrates into hepatocyte nuclei and initiates 
transcription of Notch-dependent genes, such as HES1 that promotes cyclin E to prepare for 
proliferation and inhibition of apoptosis. [9,23]. Early remodeling of the ECM induced by 
urokinase results in HGF release and activation as well as release and inactivation of TGF-β 
by alpha-2-macroglobulin. This creates an imbalance that triggers entry of hepatocytes from 
G0 to G1 phase of the cell cycle. Furthermore, EGF has an enhancing effect as its 
concentrations rise according to the increased portal flow towards a reduced liver volume 
after sHx. EGFR and MET receptor stimulation leads to the activation of NFkB, STAT3, 
PI3K, and eventually Akt [11]. NFkB activation occurs 30 minutes after sHx, which migrates 
into the nucleus to enhance transcription of multiple target genes involved in proliferation 
[24]. STAT3 activation occurs within 1 hour after sHx and lasts up to 8h [25,26], and is 
triggered by EGFR-ligands, HGF binding to the MET receptor, as well as IL6 and TNF-α 
cytokines derived from Kupffer cells [27-30]. STAT3 migrates to the nucleus and triggers 
expression of genes associated with cell cycle regulation including components of the AP1 
transcription factor, marking the activation of STAT3 crucial for G1 entry. STAT3 is thought 
to collaborate with NFkB for G0 entry, and both can be activated via IL6 signaling from 
Kupffer cells. This culmination of signals results in the activation of cyclin D1 and its 
migration to the nucleus, committing hepatocytes to enter into S phase. [31-33].  
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Although, hyperplasia is considered the core mechanism behind regeneration, upon 
30% hepatectomy, the liver also recovers its original mass via hypertrophy, i.e. the growth of 
cell size in the absence of mitoses [21,34]. Hypertrophy and the immediate gene response 
occur after both 30% and 70% hepatectomy, but only the latter loss is extensive enough to 
push hepatocytes into mitosis.   
Progression. Hepatocytes receive multiple signals from diverse mitogenic pathways not only 
to move through G1 and enter into S phase, but also to complete G2 and M phases 
(characterized as ‘delayed activation genes’, gene changes occurring from 1 hour until 
longer). It appears the cell cycle progression through S and M is driven by the same mitogens 
as the cell cycle entry, however without the activity of certain molecules considered key 
drivers of G0 entry (e.g. NFKB, STAT3). The transcription factor FOXM1 is a central 
mediator of these mitogenic pathways. FOXM1 is required for efficient S and particularly M 
phase progression during regeneration, through not only its virtue to activate S and M phase 
genes but also through repression of the cell cycle inhibitor p21 [35]. 
Termination. Termination of regeneration is the least understood phase. Near the end of 
regeneration, the ECM is being reconstructed leading to the engagement of integrins, such as 
ILK, that activate complex signaling pathways [8]. ILK pathways overall foster polarization 
and suppress hepatocyte growth [36], as seen in ILK-deficient mice subjected to sHx where 
the final liver weight substantially exceeds the pre-operative liver weight [37]. TGF-β1 and 
activin are the best known to selectively inhibit hepatocyte proliferation in the termination of 
liver regeneration. Early after sHx, TGF-β is removed from the environment of the 
hepatocyte, but is later resynthesized and restored by binding to decorin at the end of 
regeneration [38]. Decorin itself has direct inhibitory effects on both MET and EGFR [39,40] 
and the balance between binding TGF-β and acting on MET and EGFR are important in 
termination. Glypican-3 (GPC3), a protein bound to the plasma membrane of hepatocytes, 
also partakes in the growth suppressing signaling system [41]. GPC3 binds to hedgehog 
family members and may prevent them from stimulating growth in many liver cell types [42]. 
Furthermore, activins are members of the TGF-β superfamily and share similar signaling 
pathways. Activin A suppresses hepatocyte growth and is produced by hepatocytes, 
suggesting an autocrine effect [9]. Interestingly, there is a greater number of hepatocytes at 
the end of regeneration than that of the original liver and this is corrected by a small wave of 
apoptosis that occurs in the final stages [43]. Overall, termination of regeneration is based on 
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the balance between the effects of growth stimulators and mitoinhibitors, which are integrated 
into the matrix remodeling occurring after sHx.   
 
 
 
 
 
 
 
 
Figure 3. Simplified representation of mechanisms involved in the three phases of liver regeneration.  
 
Interactive mechanisms during liver regeneration 
Complex crosstalks. Liver regeneration is a complex process that is precisely orchestrated by 
autocrine, paracrine, and endocrine signaling, many of which are highly redundant [7]. These 
pathways are very complex and are interplayed throughout the various types of cells within 
the liver. Hepatocytes are the first cells to respond to regenerative stimuli, followed by biliary 
cells, and later by endothelial and stellate cells [9]. On the other hand, non-parenchymal cells 
produce early signals (i.e. Kupffer cells induce TNFα, IL6; while stellate cells produce HGF, 
hedgehog ligands, and LSECS produce WNT2 and HGF) to push hepatocytes into 
proliferation. Proliferating hepatocytes in turn synthesize growth factors effective towards 
adjacent cells, such as TGF-α, FGF1, FGF2, VEGF, angiopoietins, and PDGF. Most of these 
factors have angiogenic activity and are important for the vascular remodeling that occurs in 
later stages of regeneration. Proliferating endothelial cells and hepatocytes interact to form 
vascular channels, eventually acquiring the structure of sinusoids and restoring intact 
histology of the liver [9]. Biliary epithelial cells proliferate almost as early as hepatocytes and 
respond to the same proliferative signals (Fig 4). Lastly, there are no new portal triads and 
lobules generated in regeneration, and rather the size of the lobules of the regenerated liver 
are overall larger. 
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Other players in regeneration. Several mechanisms are continuously being studied for their 
roles in regeneration. Bile acids have been found to play a role in the progression of 
regeneration by activating the proliferative properties of the nuclear factor FXR [9,44]. The 
neurotransmitter serotonin likewise has been implicated in regeneration; however, the 
underlying mechanisms remain unclear. Recent evidence indicates it may be involved in an 
autocrine or paracrine manner in the proliferation of cholangiocytes [9,45,46]. Hypoxia has 
been shown to be an important driver of normal hepatocyte mitosis through HIF2α, which in 
parallel induces enforced VEGF production to instigate the subsequent angiogenic phase [47]. 
Lastly, regeneration is an energy-consuming process, and recently it has been shown that fat 
import from the periphery (in response to the dropping blood sugar levels following liver 
tissue loss) is required to provide regenerative fuel via β-oxidation, a process fostered by 
PTEN downregulation [48].  
Through this mechanistic summary, we can see that many studies throughout the 
decades have sought to elucidate the pathways and gene expression changes underlying liver 
regeneration after sHx; however, it still remains a complex and highly relevant topic of 
investigation (Fig 5). 
 
 
 
 
 
 
Figure 5. Overview of mechanisms involved in liver regeneration. Adapted from [7]. 
Figure 4. Coordination of 
liver cells during 
regeneration. Adapted from 
[9] with modifications.  
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3.3 The role of hepatic stellate cells role in the liver and in regeneration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 Hepatic stellate cells (HSCs), identified by von Kupffer in 1876, are liver-specific 
mesenchymal cells that are located in the space of Disse interposed between liver sinusoidal 
endothelial cells (LSECs) and hepatocytes [49]. They are often considered a substitute for 
pericytes, which support endothelial function but are absent in sinusoids. HSCs have roles in 
differentiation, proliferation, and morphogenesis of other hepatic cell types during liver 
development and regeneration. Their exact origin remains unclear as they express both 
neuroectodermal and mesodermal cystoskeletal markers [50].   
 In healthy livers, stellate cells are quiescent and contain vitamin A lipid droplets 
(comprising the largest reservoir of bodily vitamin A), regulating vitamin A homeostasis in 
the body [51]. Most of the vitamin A stored in HSCs is in the form of retinyl esters, which 
account for half of the content of lipid droplets. HSCs are also sites of β-carotene storage and 
release, which is used for retinoic acid production and maintenance of homeostasis of 
circulating carotenoids [52]. Therefore, the functions of HSCs are predominantly regulated by 
retinoic acid receptors (RARs) and peroxisome proliferator-activated receptors (PPARs). 
RARs meditate most physiological functions of vitamin A, and PPARγ is the master gene for 
adipose cell differentiation [51].  
 In liver injury, however, the natural wound healing responses are activated (in acute 
liver damage) and deregulation of these responses can result in fibrosis (resulting in chronic 
liver damage). Upon injury, hepatic stellate cells differentiate to myofibroblasts (MF). MFs 
produce increased amounts of ECM components such as collagen I and become proliferative, 
contractile, inflammatory, and chemotactic [49,53]. The expression of the cytoskeletal protein 
alpha-smooth muscle actin (αSMA) is recognized as a marker of activated HSCs [54].  
 Nevertheless, in regeneration after partial hepatectomy, a form of acute injury, TNF-α 
and IL6 secretion occurs early, primarily from Kupffer cells and to a lesser extent from HSCs. 
Matrix remodeling becomes critical and HSCs produce a number of matrix metalloproteinases 
(MMPs) to degrade the ECM and promote the release of growth factors, such as HGF [53]. 
This facilitation of forming new blood vessels is further supported by HSC-secreted 
angiopoietin 1 (ANG1), which binds to Tie-2 on LSECs to promote their close association 
and to stabilize the new vascular system [55]. HSCs also play a role in the termination of liver 
regeneration by the secretion of TGF-β1 [56]. This gives HSCs control of the balance between 
liver fibrosis and regeneration. Hedgehog signaling promotes the transition of quiescent 
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hepatic stellate cells to fibrogenic myofibroblasts, which can contribute to the epithelial 
compartment and support the regeneration of parenchyma [57]. Therefore, HSC-derived 
factors facilitate regeneration independent of direct mitogenic effects on hepatocytes (Fig 6).  
 Lastly, HSCs are also known to play a role in hepatocellular carcinoma (HCC), 
although the associations between HCC and fibrosis are incompletely understood [58,59]. 
Nevertheless, inflammatory cells, integrin signaling, growth factor interactions with the ECM, 
and communication between activated HSCs and tumor cells all play a role [60]. For example, 
activated HSCs increased proliferation and migration of human HCC cells in culture [61], 
suggesting that fibrosis promotes HCC, although not in all cases, as fibrosis and HCC could 
occur due to the same underlying factors.  
 
    
 
 
 
 
Figure 6. The role of hepatic stellate cells in regeneration. Adapted from [53]. 
 
3.4 Liver surgery and its limitations 
The fact that liver can regrow after tissue loss has enabled the surgical management of 
liver diseases, such as tumors. The progression of surgical treatment for safe removal of 
extensive tumor loads in the liver has been steadily improving since the first introduction of 
portal vein embolization (PVE) in the 1980’s [62]. The goal in surgical removal of liver 
tumors is to remove the diseased parts of the liver while maintaining enough healthy tissue to 
allow for regeneration of the organ back to its original size. However, there are many 
limitations to the removal of multiple/large tumor loads as extensive resection can lead to 
liver failure leading to small-for-size syndrome (SFSS, see below), the most frequent cause of 
death due to liver surgery.  
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The introduction of PVE was rapidly adopted through its integration into two-staged 
hepatectomies as a measure to prevent liver failure after extensive right-sided hepatectomies 
[63]. The introduction of two-staged hepatectomies was the first step-wise procedure to 
remove liver tumors where - in the first stage - PVE or portal vein ligation (PVL) prevented 
blood flow to the tumor-laden section of the liver, while smaller tumors were removed from 
the healthy non-occluded liver. The occlusion of the diseased lobe, however, led to a 
compensatory growth of the un-occluded contralateral lobe. A few weeks later, when the 
healthy contralateral lobe gained sufficient volume to sustain the patient, the second stage was 
performed, that is the resection of the atrophied tumor-laden lobe [64] (Fig 7). These 
developments led to the successful removal of multiple liver lesions that were previously 
unresectable.  
One disadvantage to this procedure is the requirement for long intervals between the 
two stages – from 2 to 13 months – in order to attain a future liver remnant large enough to 
enable stage 2. This interval presents opportunity for undesirable disease progression. 
Furthermore, insufficient hypertrophy of the healthy future liver remnant would often occur, 
preventing the feasibility of a stage 2 resection in order to avoid liver failure and the SFSS 
[65]. 
 
 
 
 
Figure 7. Pictorial example of a two-staged hepatectomy in a liver with extensive tumor load. Adapted 
from [66]. 
 
Small-for-size syndrome (SFSS) 
 SFSS is a clinical syndrome described following liver transplantation and extended 
hepatectomy. Although its pathophysiology is ill-defined, it is characterized by liver 
dysfunction (postoperative coagulopathy, persisting steatosis, hypoalbuminemia, 
hyperbilirubinemia) and regenerative deficiency due to insufficient functional liver mass. As 
already mentioned, the SFSS remains the most common cause of postoperative death, but is 
currently untreatable. It is particularly unclear whether the impaired liver function is a result 
of disproportional tissue damage after resection or secondary to a primary failure in 
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regeneration of the small remnant. At least in mice, it could be demonstrated that a transient 
cell cycle arrest is sufficient to cause classic SFSS symptoms [67], albeit in humans – unlike 
in the multilobular mouse liver- resection usually is associated with direct parenchymal 
injury. Regardless, the minimal functional future liver remnant required to avoid SFSS is ≥ 
25% in a normal liver and ≥ 40% with preoperative liver dysfunction [68]. PVE and two-
staged hepatectomies allow for volume manipulation by increasing the functional capacity of 
the liver remnant before complete resection as a preventative measure against the SFSS. 
Furthermore, many characteristics should be monitored after extended hepatectomy to help 
manage developing SFSS, such as the size of the future liver remnant, the portal blood flow 
and pressure, and assessments of serum bilirubin, albumin, and liver enzymes [69]. The most 
recent strategy to avoid SFSS and propel successful regeneration has been introduced as 
ALPPS (Associated Liver Partition and Portal vein ligation for Staged hepatectomy). 
 
3.5 ALPPS 
This innovative development in surgical treatment of extensive tumor-laden livers was 
the by-chance finding of combining portal vein ligation (PVL) with parenchymal transection 
in stage 1 of a two-staged hepatectomy. The combination of these two surgical procedures 
resulted in an enormous growth of the future liver remnant in just 8 days (compared to 2-13 
months after standard two-stage hepatectomy), allowing swift resection of the occluded 
segments in stage 2 of the procedure [70,71] (Fig 8). Since this discovery, ALPPS has been 
performed in patients with extensive liver tumor loads, although the molecular mechanisms 
behind the accelerated regeneration remain unknown.  
ALPPS in patients 
 Since ALPPS was first performed in patients in the clinic before any experimental 
models came to fruition, most publications on ALPPS are clinical observations. As already 
mentioned, portal vein ligation and parenchymal transection are performed in stage 1 with the 
diseased liver segment left in place. The ligated diseased liver acts as an auxiliary liver to 
assist the future liver remnant for the first critical week after ligation [66], and maintains some 
function, representing up to 60% of the total liver function 6 days after stage 1 of surgery 
[70]. Meanwhile, the metabolic capacity of the liver is significantly compromised after 
removal of the diseased lobe in the second stage of surgery.  
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The hypertrophy induced by ALPPS is superior to other procedures as there is an 
average 74% volume increase of the future liver remnant in a mean of 9 days [71]. Due to the 
short interval between surgical stages, tumor progression is unlikely and the second stage of 
surgery is less demanding as there are fewer adhesions allowing faster recovery for the patient 
and earlier restoration of chemotherapy [66]. The novelty of this technique is the in-situ split, 
but this surgical aspect has already been altered in the few years since the introduction of 
ALPPS in the clinic. ALPPS stage 1 was initially performed with a 100% parenchymal 
transection; however, with results eliciting a high mortality rate [72], as little as a 50% 
parenchymal transection has been determined necessary to induce the accelerated 
regeneration of ALPPS [73].  
 
 
 
 
 
Figure 8. The ALPPS procedure in human livers. Adapted from [66] 
 
ALPPS experimental models 
 Various animal models have been reported in an attempt to further understand the 
phenomenon of this accelerated liver regeneration on a molecular level. Models exist in 
mouse, rat, rabbit, swine, although there seems to be no consensus as to which lobe to assign 
as the future liver remnant. Nevertheless, amongst all these models, the common finding is 
that ALPPS-like procedures in experimental models induce similarly accelerated regeneration 
compared to portal vein occlusion alone. Primary research reveals that several pathways 
known to be involved in regeneration after partial hepatectomy have also been validated in 
ALPPS animal models. IL6, TNF-α, pSTAT3, nuclear NFkBp65, and YAP were all 
upregulated after ALPPS stage 1; whereby IL6 and TNF-α were the only molecules further 
validated in human ALPPS tissue [74-76].  
We presented the first ALPPS mouse model in 2014 [76] to study this regenerative 
phenomenon on the molecular level. Although, the liver anatomy is different in mouse, the 
ALPPS procedure was adapted to fit mouse physiology and to convey similar results (Fig 
9A). In stage 1 of murine ALPPS, 90% of the liver is ligated (with resection of the left lateral 
lobe, LLL, to mimic the ‘cleaning’ of the liver from smaller tumors) and an 80% parenchymal 
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transection is performed (Fig 9B). Just 48 hours after stage 1, the future liver remnant (the 
median left lobe, FLR), restores a volume large enough to sustain the mouse, allowing stage 2 
to be performed by resecting the atrophied ligated lobes (Fig 9C-D). Using this model 
throughout my PhD studies, I sought to complete the aims stated in the next section.  
 
 
 
 
 
 
 
 
Figure 9. Surgical procedure of ALPPS in mice. Adapted from [76].  
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3.6 Goal and aims of the PhD thesis 
 The above introduction portrays the complexity and incomplete understanding of the 
molecular changes incurred during liver regeneration after partial hepatectomy. Furthermore, 
the limits imposed on two-stage hepatectomies propelled the innovation of ALPPS, whose 
driving mechanisms have not been investigated. There exists a necessity to further understand 
these processes of regeneration with the intention of improving patient care. Indeed, the 
introduction of ALPPS has revealed that simple surgical additions can unleash an 
unprecedented acceleration of liver regeneration beyond the expected physiological limits. 
Therefore, the understanding of the molecular mechanisms underlying the acceleration of 
regeneration is not only of obvious biological interest, but might identify molecular processes 
the modulation of which could aid regeneration in the clinic. Liver regeneration after sHx 
activates molecules as early as 5 minutes after surgery. In ALPPS, we hypothesize that some 
pathways may be similar to regeneration after sHx, albeit occurring at a much faster rate, 
while others are unique and necessary to induce this accelerated regeneration.  
This PhD thesis set out to explore the pathways dysregulated in accelerated regeneration 
induced by ALPPS surgery and to assess their impact on regenerative speed. More 
specifically, after an explorative RNA deep sequencing approach, the focus prevailed to 
the following: 
1) The role of the Indian hedgehog (IHH) pathway as a unique component in the 
early induction of  accelerated regeneration as well as its mechanism of action; 
2) The identification of the upstream regulators of IHH as essential inducers of 
accelerated regeneration in ALPPS, here with a focus on JNK1. 
 
The following paragraphs provide a more detailed background on the two central pathways 
investigated in this thesis, IHH and JNK1.  
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3.7 The Hedgehog pathway 
Hedgehog signaling involves the three ligands Sonic Hedgehog (SHH), Indian 
Hedgehog (IHH), and Desert Hedgehog (DHH). All three are thought to have the same 
affinity for the receptor Patched (PTCH1); SHH and IHH are widely expressed, while DHH 
expression is limited to nervous tissue and testis [2,77]. Hedgehog ligands are lipid-modified 
proteins, meaning they can diffuse through the hydrophilic extracellular matrix and can form 
complexes with lipoproteins facilitated by glypicans. Therefore, hedgehog ligands can 
activate downstream signaling to hedgehog-responsive cells via autocrine, paracrine, or 
endocrine mechanisms [78].  
Canonical hedgehog signaling involves ligands binding to Patched (PTCH), which 
blocks its inhibitory effect on the co-receptor Smoothened (SMO), allowing SMO, a G 
protein-coupled receptor, to transduce hedgehog-initiated signals intracellularly. Active SMO 
releases GLI from its suppressor complex (Fused kinase and Suppressor of Fused), where it 
can translocate into the nucleus to promote transcription of its target genes. There are three 
GLI family members: GLI1, GLI2, and GLI3; where GLI1 is a transcription activator and is 
transcriptionally regulated by hedgehog signals, GLI2 also functions as a transcription 
activator, while GLI3 functions as a transcription repressor [2,79] (Fig 10). However, 
hedgehog signaling is also associated with non-canonical pathways. These are categorized as 
ligand-independent activation of the downstream hedgehog pathway, signaling through the 
ligand independently of GLI, and cross-talk of hedgehog components with other pathways. 
For example, TGF-β can activate GLI2 directly, independently of SMO. PTCH can also 
directly interact with cyclin B1 and caspases, omitting interaction with GLI to inhibit cell 
proliferation and promote apoptosis [80].  
(A)         (B) 
 
 
 
 
Figure 10. Hedgehog signaling in the (A) absence (B) or presence of Hedgehog ligands. Adapted from 
[78]. 
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During development, the hedgehog ligands are essential morphogens. They are 
secreted by various cells, diffuse throughout the embryo, and modulate cell fate as a function 
of ligand concentration [81]. Hedgehog regulates several key cell functions, namely 
proliferation, survival, migration, and differentiation [78]. Inhibition of the hedgehog pathway 
during development leads to many defects including failure of brain development and skeletal 
defects [82]. However, in the healthy, resting adult liver, there is minimal hedgehog activity.  
Chronic liver injury or tissue loss reactivate the hedgehog pathway to modulate liver 
repair. Upon injury, hepatocytes, LSECs, myofibroblastic HSCs, NKT cells, and Kupffer cells 
induce expression of SHH and IHH. Therefore, most stromal cells that accumulate in injured 
livers are capable of activating the canonical hedgehog pathway, promoting viability, growth, 
activation, and transition towards a more mesenchymal phenotype [2]. HSCs are particularly 
responsive to hedgehog ligands, and hedgehog enhances HSC survival by inhibiting 
apoptosis, promoting HSC proliferation, and stimulating HSCs to acquire a myofibroblastic 
phenotype [83].  HSC activation can also be induced by mitogens again in a hedgehog-
dependent way [84].  
During regeneration following tissue loss such as after sHx, hedgehog pathway 
activation is required for a normal healing response. The expression of hedgehog ligands and 
GLI2 increases 24-48 hours after sHx in mice, paralleling maximal hepatocyte proliferative 
activity. Furthermore, inhibition of the hedgehog pathway by the SMO-specific inhibitor 
cyclopamine reduced hepatocyte proliferation, blocked restoration of liver mass, and reduced 
posthepatectomy survival [85]. Currently, it is not known whether one or all hedgehog ligands 
are contributing to the regenerative process. Interestingly, the binding of IHH to GPC3 
decreases dramatically during the proliferative phase post hepatectomy, while IHH is re-
sequestered by GPC3 towards the end of regeneration, perhaps suggesting IHH is transiently 
freed to support regeneration after tissue loss [86].  
On the other hand, prolonged overactivation of the hedgehog pathway appears to 
promote chronic liver disease and carcinogenesis. For example, pharmacological inhibition of 
the hedgehog pathway by cyclopamine protects mice from developing chronic liver disease 
[87]. Hedgehog pathway activity has been consistently identified in about two-thirds of HCC 
tumors, while the physiological inhibitor of hedgehog, HHIP, is epigenetically silenced in 
liver cancer [88]. Hedgehog activation correlates with tumor size, capsular invasion, vascular 
invasion, higher tumor stage, intrahepatic metastasis, decreased survival, and recurrence after 
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curative resection [2]. Furthermore, preclinical studies in mice show that inhibiting the 
hedgehog pathway via SMO reduces tumor size and regresses HCC [89]. 
Overall, the hedgehog pathway is a master regulator of the repair response after adult 
liver injury, but also determines the extent of chronic liver damage. Therefore, appropriate 
control of hedgehog signaling is essential for normal liver function to orchestrate hepatic 
wound-healing, inflammation, vascular remodeling, fibrogenesis, and epithelial regeneration.  
The Hedgehog pathway in ALPPS 
Our aim was to explore dysregulated pathways in ALPPS compared to surgical 
controls at early time points after operation through RNA deep sequencing of liver tissue. We 
identified Ihh as a top upregulated gene unique in ALPPS at 4 hours after operation. We 
explored the role of hedgehog signaling in the context of accelerated liver regeneration 
through western blots, immunohistochemistry, and PCR. Our findings show that IHH 
secretion from stellate cells peaks at 4 hours after ALPPS to activate the translocation of GLI1 
into the nucleus, leading to the subsequent upregulation of GLI1’s key proliferative target 
gene, Ccnd1, along with increased hepatocyte proliferation. The necessity of IHH in the 
ALPPS regenerative response was confirmed by the in vivo inhibition of IHH through a 
neutralizing antibody, as well as the replication of its accelerating effects with recombinant 
IHH protein.  
 
3.8 The JNK pathway 
 c-Jun NH2-terminal kinases (JNKs) are members of the mitogen-activated kinase 
(MAPK) family. In the context of tissue regeneration, JNKs have been shown to regulate 
processes to ensure (i) proper repair of cells sustaining minor damage and (ii) elimination of 
cells sustaining irreversible damage, including their proper replacement [2]. Three genes, 
Mapk8, Mapk9, and Mapk10 encode JNK proteins JNK1, JNK2, and JNK3 respectively. 
JNK1 and JNK2 are ubiquitously expressed, while JNK3 is largely restricted to neuronal cells 
[90]. A wide range of stimuli including UV- and γ-radiation, cytokines, bacterial products, 
and endoplasmic reticulum stress activate JNKs. Activation of JNKs occurs through a three-
tier phosphorylation cascade involving MAPK kinase kinases (MKKKs) and two mitogen-
activated protein kinase kinases (MKKs) that dually phosphorylate JNK1 at threonine and 
tyrosine residues to unfold their activity [91]. JNKs then target c-Jun that dimerizes to form 
the activating protein-1 (AP-1) transcription factor complex. JNKs additionally phosphorylate 
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other transcription factors, nuclear hormone receptors, scaffold proteins, ubiquitin ligases, 
kinases, cytoskeletal proteins, and BCL2 family members, likely contributing to JNKs 
varying functions [92]. Furthermore, JNK1 and JNK2 share some downstream genes leading 
to redundant function, although many gene targets differ [93,94].  
The JNK signaling cascade promotes proliferation in several ways [2]:  
(i) activation of cyclin D1, cyclin E-dependent kinases (CDKs) and transcription 
factor E2F,  
(ii) repression of the tumor suppressor gene p53 and its target gene, p21, and  
(iii) direct phosphorylation of Cdc25C to negatively regulate its phosphatase 
activity and to activate Cdk1 enabling timely control of mitosis onset.  
JNK1 seems to mediate the majority of proliferation as with only JNK1- but not JNK2-
deficient fibroblasts do proliferation rates decrease [95]. 
 In liver regeneration after sHx, JNK – notably JNK1 - is strongly upregulated, leading 
to AP-1 activation, the promotion of cyclin D1 expression, and G0 to G1 transition. Inhibiting 
JNK activity by SP600125, a specific JNK inhibitor, not only impairs liver regeneration but 
also decreases the expression of cyclin D1 along with reduced hepatocyte proliferation [96].  
 However, in liver injury, JNK activation prolonged by sustained TNF-α stimulation 
induces a c-Jun-dependent mitochondrial death pathway, a process involved in the 
pathophysiology of many types of liver injury such as viral hepatitis or alcoholic liver disease, 
resulting in cell death-promoting effects [97].  Examples of prolonged JNK expression in liver 
disease states include increased JNK activity in acetaminophen-induced liver failure in both 
mice and humans [98], JNK upregulation following ischemia-reperfusion during 
transplantation that contributes to hepatic reperfusion injury [2], and JNK1’s role in fibrosis 
with the activation of HSCs and the promotion of ASMA expression [99]. Furthermore, 
chronic activation of JNK has been associated with the development and progression of 
hepatocellular carcinoma (HCC). Consistent JNK1 activity has been reported to predict a bad 
outcome in HCC, an aspect that perhaps relates to JNK1 activation secondary to chronic liver 
injury, an accepted cause of HCC. Although the proapoptotic function of JNK1 has been 
related to anti-cancerous actions [100], recent evidence indicates a more complex situation, as  
JNK1 may directly promote the repair of DNA breaks [101]. These observations suggest a 
disturbed balance between the removal or repair of damaged hepatocytes that underlies 
JNK1's association with a bad HCC outcome [101]. There is evidence that JNK acts as a key 
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mediator by promoting an inflammatory environment, although the underlying mechanisms 
are unclear [102]. Lastly, JNK1 promotes the development of nonalcoholic steatohepatitis 
(NASH) through various mechanisms including promotion of adiposity and steatosis, 
increased cell death and increased inflammation, whereas JNK2 exerts cytoprotective effects 
in fatty liver disease [2]. 
 Therefore, the biological role of JNK can be contradictory and complex depending on 
the molecular environment. Overall, it seems that short-term activation of JNK exerts 
cytoprotective effects in the liver, while prolonged JNK activity is associated with cell death 
and disease.  
The JNK pathway in ALPPS 
 By in-silico analysis of possible upstream regulators of IHH, we identified Mapk8 
(JNK1) to be upregulated in stellate cells 1 hour after ALPPS, preceding the 4 hour IHH peak 
we previously identified. Through specific JNK inhibition with SP600125, we established that 
JNK1 induces the IHH-GLI1-cyclin D peak after ALPPS as an essential pathway in 
accelerated regeneration. Furthermore, the use of recombinant IHH after JNK-inhibition 
rescued the regenerative effects of ALPPS, indicating JNK1 acts through IHH, a hitherto 
undescribed interaction in a regenerative model. 
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Abstract 
Background & Aims: ALPPS, a novel two-staged approach for the surgical removal of large/multiple 
liver tumors, combines portal vein ligation (PVL) with parenchymal transection. This causes 
acceleration of compensatory liver growth, enabling faster and more extensive tumor removal. We 
sought to identify the plasma factors thought to mediate the regenerative acceleration following 
ALPPS.  
Methods: We compared a mouse model of ALPPS against PVL and additional control surgeries (n=6 
per group). RNA deep sequencing was performed to identify candidate molecules unique to ALPPS 
liver (n=3 per group). Recombinant protein and a neutralizing antibody combined with appropriate 
surgeries were used to explore candidate function in ALPPS (n=6 per group). Indian hedgehog 
(IHH/Ihh) levels were assessed in human ALPPS patient plasma (n=6).  
Results: ALPPS in mouse confirmed significant acceleration of liver regeneration relative to PVL 
(p<0.001). Ihh mRNA, coding for a secreted ligand inducing hedgehog signaling, was uniquely 
upregulated in ALPPS liver (p<0.001). Ihh plasma levels rose 4h after surgery (p<0.01), along with 
hedgehog pathway activation and subsequent cyclin D1 induction in the liver. When combined with 
PVL, Ihh alone was sufficient to induce ALPPS-like acceleration of liver growth. Conversely, 
blocking Ihh markedly inhibited the accelerating effects of ALPPS. In the small cohort of ALPPS 
patients, IHH tended to be elevated early after surgery.  
Conclusions: Ihh and hedgehog pathway activation provide the first mechanistic insight into the 
acceleration of liver regeneration triggered by ALPPS surgery. The accelerating potency of 
recombinant Ihh, and its potential effect in human ALPPS may lead to a clinical role for this protein.  
Lay Summary: ALPPS, a novel two-staged hepatectomy, massively accelerates liver regeneration, 
thereby helping treat patients with otherwise unresectable liver tumors. The molecular mechanisms 
behind this accelerated regeneration are unknown. Here, we elucidate that Indian hedgehog, a secreted 
ligand important for fetal development, is a crucial mediator of the regenerative acceleration triggered 
by ALPPS surgery 
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Introduction 
The liver is unique with regards to its 
regenerative capacity. Its ability to regrow 
after tissue loss has permitted the surgical 
removal of large or multiple liver tumors with 
curative intent. Physiological limits to liver 
regeneration nevertheless exist. When the 
functional liver remnant is too small, the liver 
cannot recover vital function due to deficient 
hepatocyte proliferation [1, 2]. In the clinic, 
resection-induced liver failure is known as the 
small-for-size syndrome (SFSS) and represents 
the most frequent cause of death due to liver 
surgery [3, 4].  
To reduce the risk of SFSS and to expand the 
application of surgery, two-staged 
hepatectomies (TSHs) have been developed. In 
a first step, the portal veins of one (i.e. the 
diseased) liver section are occluded, causing 
compensatory growth of the non-occluded (i.e. 
healthy) part. The thereby increased liver 
volume enables extended liver resection in a 
second step. While the combination of portal 
vein ligation (PVL) with later resection have 
become standard strategies [4,5], liver growth 
after PVL is slow and sometimes insufficient 
to enable TSH completion or prevent SFSS 
[6]. Even if successful, several months can 
pass until resection can be performed, 
increasing the likelihood of disease 
progression and complicating surgery due to 
developing tissue adhesion [7].  
In the past few years, a novel two-staged 
approach, associating liver partition and portal 
vein ligation for staged hepatectomy (ALPPS), 
has been designed. This procedure has the 
potential to avoid most of the drawbacks 
associated with conventional TSHs [8, 9]. 
ALPPS differs from conventional TSHs in that 
step one combines PVL with the additional 
transection (an in situ split) along the 
demarcation between the occluded and non-
occluded liver. Intriguingly, the PVL-
transection combination causes an 
unprecedented acceleration of compensatory 
liver growth [8, 9]. Within 9 days after PVL-
transection, an average 74% volume increase 
of the non-occluded lobe has initially been 
reported [9], greatly reducing the time interval 
to resection. Extrapolated liver growth rates 
after ALPPS may be up to 11 times higher than 
after PVL [7]. In other words, ALPPS enables 
surgery in patients otherwise deemed as 
unresectable due to marginal liver remnants 
with high SFSS risk [9, 7]. Whereas optimal 
conditions for the application of ALPPS are 
still being defined, a marginal size of the liver 
remnant appears to be of small concern for 
ALPPS [10].  
The acceleration of liver regeneration observed 
after ALPPS inquires for the nature of 
underlying mechanisms. Consequently, we 
have developed the first animal model of 
ALPPS that is based on the adaptation of 
human surgery to mouse liver architecture 
[11]. Akin to the human operation, PVL plus 
transection in mice massively accelerates the 
regenerative speed compared to PVL alone. 
When PVL-transection is completed as a first 
step, the second step (i.e. extended resection) 
is performed 48h later, leading to completed 
regeneration within 4 days despite starting 
from a remnant with only 10% of the original 
liver volume [11]. In comparison, regeneration 
after standard 70%-hepatectomy (leaving a 
30% remnant) needs about a week for 
completion in mice, while a 90%-hepatectomy 
is lethal [1, 2]. Intriguingly, plasma obtained 
from mice subjected to ALPPS step 1 
comparably accelerates regeneration when 
injected into mice subjected to PVL only [11]. 
Therefore, ALPPS in mice seems to trigger 
unknown circulating factors that mediate 
regenerative acceleration and hence might be 
of therapeutic interest.  
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This study was set out to obtain a first insight 
into the molecular mechanisms underlying 
ALPPS-triggered acceleration of liver 
regeneration. We sought to uncover a plasma 
factor that is induced by ALPPS step 1 to 
accelerate PVL-mediated liver regeneration. 
By using an unbiased expression profiling 
approach in comparing ALPPS step 1 with 
PVL, transection, and control surgery, we 
identified Indian hedgehog (Ihh) as a plausible 
candidate. We then explored the role of Ihh in 
the acceleration of PVL-induced regeneration 
and tested the dependency of ALPPS on 
circulating Ihh. Altogether, we describe 
circulating Ihh as a key component mediating 
early acceleration of liver regeneration 
following ALPPS surgery. 
 
Materials and Methods 
Animals 
All animal experiments were performed in 
accordance with Swiss Federal Animal 
Regulations and approved by the Veterinary 
Office of Zurich. Male C57Bl/6 mice (Envigo, 
Horst, NL)  aged 10-12 weeks kept on a 12-
hour day/night cycle with free access to food 
and water were used. 
Animal surgery and treatment  
To mimic human ALPPS surgery in mice, 90% 
PVL was performed leaving a 10% functional 
remnant consisting of the left and a part of the 
right middle lobe. Then, a partial 80% 
transection was done through the middle lobe 
along the demarcation line of the 
occluded/non-occluded parenchyme. The left 
lateral lobe (LLL, 25% of liver volume) was 
also resected to simulate the cleaning of the 
liver from smaller tumors as often done in 
human ALPPS (Fig. 1A). Left lateral lobe 
resection (LLLx) does not induce significant 
regeneration in mouse and is comparable to 
sham. Details on isoflurane anesthesia, 
buprenorphine analgesia, ALPPS procedures, 
and the control operations (90% PVL, 80% 
transection, LLLx, and sham laparotomy) have 
been described [11]. After surgery, animals 
were allowed to recover on a warming pad in a 
separate cage until completely conscious. 
Standard (68%) hepatectomy was performed as 
described [1]. Animals were weighed before 
surgery and at sacrifice, where weight of 
resected and remnant liver was recorded. 
Tissue was formalin fixed or snap frozen, 
while plasma was stored at -80°C for analysis.  
Recombinant Ihh (200 ng/kg, 160l final 
volume; R&D, 1705-HH-025/CF Minneapolis, 
MN) or PBS was injected into the vena cava 
right after PVL. Ihh antibody (4ug/kg, 160l 
final volume; R&D MAB8048) or PBS was 
injected via tail vein one hour before 
operation.  
Liver regeneration  
Liver regeneration was assessed by the 
percentage of functional-liver-remnant-to-the-
body weight ratio (FLR/BW) derived from six 
animals per group and time point.  
Quantitative real-time PCR  
Total RNA was extracted from 50 mg of tissue 
using Trizol reagent following provided 
instructions (Invitrogen, Basel, Switzerland). 
RNA quality/quantity was assessed using a 
spectrophotometer and converted to cDNA 
briefly as follows: a reaction was prepared 
with the Taqman Fast Universal PCR Master 
Mix, no AmpErase UNG (ThermoFischer 
Scientific, cataloque number 4352042), (4μl in 
a 20 μl reaction with 1 μg RNA). A 5 min 
incubation at room temperature was 
performed, followed by an incubation at 42°C 
for 30 min, and lastly an incubation at 85°C for 
5 min. qPCR was performed with two 
replicates/sample on cDNA (Thermo Script 
reverse transcription PCR System, Invitrogen) 
using an ABI Prism 7500 Sequence Detector 
system (PE Applied Biosystems Rotkreuz, 
Switzerland). Taqman gene expression assays 
(Applied Biosystems) are listed in 
Supplementary Table 1. Results represent 
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mean fold induction (2
-ΔCt
) ±SD relative to the 
normalization control 18S rRNA [1].  
Immunohistochemistry  
Archived liver sections (3 μm) were stained 
(antibodies in Supplementary Table 2) using 
the Dako Autostainer Link48 Instrument and 
the iView 3,3-diaminobenzidine (DAB) kit 
(Dako Denmark A/S). Antibodies are listed in 
Supplementary Table 2. Quantification of 
Ki67- and pH3-positive hepatocytes was done 
by blinded manual counting in ten random 
visual fields (20x).  
RNA deep sequencing  
Total liver RNA prepared by DNA Column 
Clean-up (Qiagen, Basel, CH) was deep 
sequenced by the Functional Genomics Center 
Zurich using poly-A selection on the Illumina 
Hiseq 2500. A QC report was generated and 
two-group analyses (comparing all procedures 
normalized to sham) were performed to 
retrieve differential gene expression data. Data 
were analyzed for pathways and genes unique 
to ALPPS through Metacore (filter criteria, 
p<0.05 and log2ratio>4). All data have been 
deposited to the European  Nucleotide Archive 
(ENA) under the accession number 
PRJEB15593.  
Western blotting 
 Blotting was performed as described [1]. 
Antibodies are listed in Supplementary Table 
2. NE-PER Nuclear and Cytoplasmatic 
Extraction reagents (Thermo Fisher Scientific, 
Waltham, MA, PK207589) were used to 
isolate subcellular fractions, with their 
separation ascertained through β-tubulin 
(cytoplasmic) and lamin B1 (nuclear) blotting.  
Hedgehog ligand levels  
Ihh/IHH and sonic hedgehog (Shh) protein 
levels were measured by ELISA (mouse Ihh: 
Cusabio, CSB-E16517m; human IHH: CSB-
E12007h; mouse Shh: R&D, MSH00).  
Human samples 
 EDTA-blood was obtained from ALPPS 
patients (n=6) directly (t=0, baseline) or 2h, 
24h, and 48h after transection (step 1). Plasma 
was stored at -80°C. The use of human 
samples was approved by the cantonal ethics 
committee Zürich (KEK-ZH-Nr. 2015-057). 
Informed consent was obtained from all 
patients. See Supplementary Table 3 for 
patient description.  
Statistical Analysis 
Data are expressed as mean ±SD. Differences 
between groups (n=6/group unless for 
expression profiling where n=3/group) were 
determined using unpaired, two-tailed t tests 
assuming unequal variance via GraphPad 
Prism v4.0 (GraphPad, San Diego CA), with 
significance set at P<0.05. Analyses were 
blinded.  
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Results 
The ALPPS model of accelerated liver 
regeneration 
To study mechanisms underlying the ALPPS-
associated acceleration of liver regeneration, 
we used our recently developed mouse model 
of ALPPS [11]. Liver weight gain induced by 
ALPPS (here specifically referred to PVL-
transection-LLLx, see Fig. 1A and Methods 
for explanation) was compared to appropriate 
control surgeries (PVL, transection, LLLx, 
sham laparotomy) in order to ascertain 
acceleration of regeneration (see 
Supplementary Fig 1. for a comparison with 
hepatectomy). All procedures similarly 
affected body weight (Fig. 1A). LLLx alone 
did not induce significant liver weight regain, 
akin to transection only. As expected, PVL led 
to a steady weight gain, while ALPPS 
markedly accelerated regeneration relative to 
PVL (Fig. 1B). Acceleration was particularly 
evident during the first 12-24h, and ALPPS 
elevated the number of hepatocytes positive 
for Ki67 (cycling cells) and bold pH3 (marking 
mitotic cells [1]) at 4h and particularly 8h 
compared to PVL (Fig 1B). Next, we assessed 
the expression of key cell cycle molecules, the 
cyclins, most of which were elevated at 8h 
after ALPPS. Ccnd1 mRNA (encoding cyclin 
D1, a crucial promoter of the hepatocyte cell 
cycle [12]) displayed an ALPPS-specific peak 
at 8h (Fig. 1C) akin to pH3 counts, while the 
cell cycle inhibitor p21 [1] was downregulated 
(Fig. 1D, see Supplementary Fig. 2 for 
immunoblot bands) in ALPPS vs PVL. At 12h 
however, p21 was upregulated in ALPPS and 
associated with a drop in Ki67/pH3 counts, 
perhaps due to a small negative feedback to 
prevent exuberant proliferation in response to 
the massive regenerative activity elicited 
through ALPPS [13]. Together, these findings 
indicate that ALPPS accelerates liver weight 
regain and hepatocellular cell cycle at early 
times after surgery. Therefore, key pathways 
must operate early after ALPPS to accelerate 
regeneration.    
Indian hedgehog as a candidate plasma 
factor associated with ALPPS 
To obtain unbiased insight into potential 
ALPPS-associated molecular alterations in the 
liver, we deep-sequenced hepatic RNA during 
the first 12h after ALPPS, PVL, transection, 
LLLx, and sham operation. A distinct gene 
expression profile was evident for ALPPS as 
early as 4h post operation (Fig. 2A, 
Supplementary Fig. 3). At this time point, 
MetaCore analysis (Fig. 2B) revealed two 
pathways unique to ALPPS, the "TGF-beta-
dependent induction of EMT via MAPK" 
(P=5.9
-14
, false discovery rate [FDR]=3.18
-12
) 
and the "Sirtiun6 regulation and function" 
(P=1.17
-13
, FDR=5.48
-12
) pathway 
(Supplementary Table 4). MetaCore analysis 
further revealed 50 independent genes unique 
to ALPPS (Fig. 2C, Supplementary Table 5). 
The only gene common to both the ALPPS-
specific pathways and independent genes was 
Ihh (log2ratio=6.0, FDR=2.96
-30
), a secreted 
hedgehog ligand. PCR revealed an ALPPS-
specific Ihh mRNA peak at 4h, while hepatic 
protein levels were reduced (Fig. 2D). Plasma 
protein levels however peaked at 4h after 
ALPPS (Fig. 2D), together suggesting newly 
produced Ihh was not being retained within 
cells but immediately secreted into plasma. 
Thus, Ihh may fit the role of a postulated 
plasma factor released through ALPPS. No 
ALPPS-specific changes were detected for 
other hedgehog ligands (desert hedgehog 
(Dhh), Supplementary Fig. 4). Non-
parenchymal cells, particularly stellate cells, 
were positive for Ihh across samples (Fig. 2E, 
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Supplementary Fig 5), suggesting the ligand is 
sourced from the stellate population.  
Ihh pathway activity is elevated after ALPPS 
To substantiate Ihh as a candidate behind 
ALPPS-accelerated liver regeneration, we 
assessed hedgehog pathway components in 
liver. Ihh binds to its receptor Ptch1, relieving 
inhibition of Smo, which then causes nuclear 
translocation of the Gli transcription factors, 
the downstream effectors of hedgehog 
signaling [14]. No differences between ALPPS 
and PVL were observed for Ptch1 and Smo 
expression, while Gli1 and Gli2 alterations 
showed significant differences. However, Hhip 
(encoding the hedgehog ligand inhibitor) was 
downregulated at 4h and particularly 8h post 
ALPPS, relative to PVL/transection (Fig. 3A). 
Immunoblots on cytosolic and nuclear 
fractions revealed that nuclear Gli1, but not 
Gli2, was upregulated at 4h in ALPPS vs 
PVL/transection. Immunofluorescence 
localized upregulation of Gli1 to hepatocyte 
nuclei of ALPPS liver (Fig. 3B). At 8h, Gli1 
was not elevated in ALPPS nuclear fractions. 
Unlike in PVL/transection however, the main 
Gli1 signal remained in hepatocyte nuclei of 
ALPPS liver (Fig. 3B). Accordingly, both the 
Gli1 target cyclin D1 (Supplementary Fig. 6; 
Fig. 1C for mRNA) and mitotic counts (Fig. 
1B) peaked at 8h, associating hedgehog 
activity in hepatocytes with their proliferation. 
Together with Hhip downregulation at 4-8h, 
Ihh signaling in liver may hence be conducive 
to acceleration of liver regeneration following 
ALPPS.  
Recombinant Ihh accelerates PVL-induced 
liver regeneration 
If Ihh mediates acceleration of regeneration 
after ALPPS, combining Ihh with PVL should 
mimic the effects of ALPPS. Mouse 
recombinant Ihh was administered after PVL 
instead of transection. When assessing body 
weight after injection, no differences were 
observed between PVL-Ihh and PVL-PBS 
animals. In contrast, liver weight was 
significantly elevated after PVL-Ihh compared 
to PVL-PBS - akin to levels after ALPPS 
surgery, albeit with different kinetics (Fig. 
4A). The assessment of proliferation markers 
revealed increasing pH3 counts, with 
elevations particularly evident at 12h after 
PVL-Ihh (Fig. 4B). qPCR suggested relative 
Gli1 and Ccnd1 upregulation as well as Hhip1 
downregulation in PVL-Ihh liver over time 
(Fig. 4C). Gli2 (Fig. 4C), Ptch and Smo were 
largely unaffected by Ihh (Fig. 4C). Nuclear 
protein levels of Gli1, but not Gli2, were 
upregulated through Ihh relative to PBS 
treatment, however at times later than 4h (Fig. 
4D). Accordingly, cyclin D1 protein levels 
(Fig. 4E) and hepatocellular expression 
(Supplementary Fig. 7) were elevated after 
PVL-Ihh particularly at 12h. Altogether, the 
combination of PVL with Ihh has effects on 
regeneration similar to ALPPS, albeit in a 
delayed manner. These findings identify Ihh as 
an accelerator of PVL-induced liver growth.   
Ihh neutralization deaccelerates ALPPS-
induced liver regeneration. 
If Ihh mediates accelerated regeneration after 
ALPPS, blocking Ihh should inhibit the 
ALPPS effects. A neutralizing antibody 
against Ihh was injected 1h prior to ALPPS 
surgery. Compared to PBS injection, body 
weight remained unaffected. Instead, Ihh 
neutralization reduced liver weight gain after 
ALPPS, although not to levels seen after PVL 
only (Fig. 5A). Proliferation parameters 
confirmed the deaccelerating effect of Ihh 
inhibition, illustrated through the suppression 
of the 8h-pH3 peak seen after ALPPS (Fig. 
5B). Relative to PBS, αIhh upregulated Hhip 
but lowered Gli1/2 and Ccnd1 expression in 
liver of ALPPS mice (Fig. 5C). Moreover, 
nuclear levels of Gli1, but not Gli2, were 
reduced over time through αIhh-treatment (Fig. 
5D). Finally, both cyclin D1 levels (Fig. 5E) 
and hepatocyte expression (Supplementary 
Fig. 7) were lowered in the ALPPS-αIhh 
relative to the ALPPS-PBS group. We 
conclude Ihh is an important mediator of the 
ALPPS effects.  
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Combined with our other data, these findings 
indicate that the elevations in plasma Ihh 
observed after ALPPS are central to the 
acceleration of liver regeneration achieved 
through this surgical technique.  
IHH is induced in human ALPPS 
Hedgehog signaling is conserved among 
animals [15]. To estimate whether ALPPS-
induced Ihh elevations in mice are of human 
relevance, we measured plasma IHH levels 
from six consecutive patients having 
undergone ALPPS surgery at our clinic. 
During the first 24h, IHH levels were elevated 
over baseline levels at the time of surgery (Fig. 
6). Given the slower regenerative pace in man 
relative to mouse, these observations are 
consistent with an early upregulation of IHH 
plasma levels in patients subjected to ALPPS 
surgery. No correlation was detected between 
IHH levels and postoperative liver volume or 
complication scores (IHH plasma levels 
correlated to % increase FLR, R² = 0.1047; 
IHH plasma levels correlated to 
comprehensive complication index (CCI) 
scores, R² = 0.4973), however analysis was 
hampered through the small and heterogeneous 
patient group (Supplementary Table 3). There 
was no ‘control surgery’ in the human patients, 
due to the nature of the clinical trial from 
which the tissue samples were obtained. 
Therefore, no statistical calculation were 
carried out. 
Discussion 
The development of ALPPS surgery has 
pushed the limits of resectability in liver 
surgery. The need to keep a certain remnant 
volume for liver to recover after tissue 
resection is a serious constraint that hinders the 
management of liver malignancy. The ALPPS 
approach illustrates that a conceptually simple 
combination of existing surgical techniques 
with a novel maneuver can unleash biological 
processes which are surprising in their extent. 
In other words, ALPPS demonstrates that the 
intrinsic capacity of liver to regenerate is larger 
than we think, but usually is cabined, likely to 
gain in stability and reliability needed for long-
term function.  
Mechanistically, liver regeneration after simple 
resection is highly complex [16]. How PVL 
leads to contralateral liver growth is ill-
understood [17], and how regeneration is then 
accelerated by a transection step is unknown. 
The observation, however, that plasma 
obtained from ALPPS mice can mediate 
acceleration [11], pointed to circulating 
molecules being responsible for the effect of 
ALPPS. Here, we identify Ihh as one key 
plasma factor that is triggered by ALPPS step 
1 to mediate early acceleration of liver 
regeneration.  
Following an explorative transcriptome 
profiling approach, we found Ihh as the most 
likely gene to be specifically induced by 
ALPPS in liver. Its hepatic mRNA levels peak 
at 4h after surgery, paralleled by increases in 
Ihh plasma levels, consistent with Ihh acting as 
an auto/paracrine ligand following its secretion 
from stellate cells [14]. The time after the Ihh 
peak (4-8h) is associated with a marked 
increase in proliferation markers in ALPPS 
relative to PVL, along with an ALPPS-specific 
peak in the expression of Ccnd1, crucial for the 
hepatocellular cell cycle progression [12]. 
Cyclin D1 is a target of hedgehog signaling 
and required for successful liver regeneration 
after tissue loss [18, 19, 12], consistent with a 
key role for Ihh in the ALPPS effects. 
Although the levels of plasma Ihh and of 
nuclear Gli1 (the hedgehog effector inducing 
Ccnd1) in hepatocytes were highest at 4h after 
ALPPS, cyclin D1 and mitoses (pH3) did not 
peak before 8h. At 8h however, the nuclear 
Gli1 signal remained localized to hepatocytes 
particularly in ALPPS liver, despite similar 
overall expression levels to PVL and 
transection. On the other hand, the hedgehog 
ligand inhibitor Hhip was most downregulated 
in ALPPS at 8h relative to PVL/transection, 
providing an explanation for the persistence of 
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hepatocellular Gli1 activity at this time [14]. 
These findings suggest an ALPPS-specific Ihh 
wave induces sustained hedgehog activity in 
hepatocytes, eventually causing cyclin D1 
upregulation to promote cell cycle progression. 
Therefore, ALPPS-triggered hedgehog 
pathway activity in hepatocytes appears to rely 
not only on the level of Gli1, but also on the 
duration and location of Gli1 activity. The 
associated proliferative peak at 8h is then 
likely to lead to the rapid gain in liver weight 
early post-surgery. Cellular hypertrophy or 
lipid accumulation might contribute to weight 
gain, however, ALPPS causes neither 
hypertrophy (Supplementary Fig. 8) nor 
significant steatosis (Fig. 1B, H&E) at early 
times.  
To establish a role for Ihh in ALPPS, we 
injected recombinant protein into PVL mice. 
Indeed, regeneration was accelerated and 
accompanied by increases in proliferation, 
Gli1 and cyclin D1 along with Hhip 
downregulation. Of note, the response to 
recombinant Ihh was somewhat delayed 
compared to ALPPS. A likely explanation for 
this delay is that injection of recombinant Ihh 
cannot fully mimic the ALPPS-triggered Ihh 
wave, as both local Ihh concentrations and 
protein modifications will differ between 
ALPPS and Ihh injection [20]. Nonetheless, 
our findings demonstrate that plasma Ihh alone 
is sufficient to push regeneration induced by 
PVL. Conversely, ALPPS markedly lost its 
accelerating effects - again paralleled by 
according changes in proliferation and 
hedgehog components - when circulating Ihh 
was blocked, confirming that the regenerative 
potential unleashed by ALPPS strongly 
depends on the elevations in Ihh. However, 
some acceleration was still evident after Ihh 
neutralization, suggesting ALPPS induces 
additional factors with a pro-regenerative 
effect. In our screen, we did not detect ALPPS-
specific changes in molecules classically 
involved in liver regeneration, such as Hgf, 
Egf or Tnf (Supplementary Fig. 9). However, 
we have already reported very early increases 
in plasma Il-6 after ALPPS surgery, suggesting 
this molecule may contribute to the ALPPS 
effects [11]. Altogether, our findings reveal a 
key role for Ihh in the acceleration of PVL-
induced liver growth. Future research will need 
to explore the nature and kind of additional 
factors that participate in the accelerating 
effects of ALPPS.  
Hedgehog signaling is known to be required 
for liver regeneration after both chemical 
insults and resection. Interestingly, the 
pathway is thought to operate in activated 
stellate cells that then promote parenchymal 
proliferation [21, 22]. At the Ihh 
mRNA/plasma peak after ALPPS, we 
observed Ihh staining in non-parenchymal 
cells, often displaying typical stellate 
morphology (Supplementary Fig. 5). Hence, 
ALPPS appears to trigger Ihh production in 
stellate cells but not hepatocytes [14]. 
Additional contributions to the elevations in 
circulating Ihh perhaps might come from other 
non-parenchymal cells or from the 
extracellular matrix, which can release the 
ligand during regenerative remodeling [23]. 
Early after hepatectomy, hedgehog signaling 
first acts in an autocrine way to promote the 
conversion of stellate cells into epithelial 
progenitors able to repopulate a part of the lost 
parenchymal mass [21, 22]. At 48h post-
hepatectomy, signaling likewise becomes 
paracrine, resulting in Gli nuclear 
accumulation in hepatocytes to promote 
parenchymal reconstitution directly from 
epithelium [24]. After ALPPS, Gli1 is 
observed in nuclei of hepatocytes and stellate 
cells already at 4h, suggesting that the Ihh 
wave either simultaneously induces autocrine 
and paracrine signaling, or greatly accelerates 
the events observed after hepatectomy [21, 22, 
24]. Therefore, while hedgehog signaling may 
not be specific to ALPPS, the timing of 
pathway activation through early Ihh release is 
unique to this procedure. Whether hedgehog 
signaling after ALPPS otherwise operates in 
analogy to hepatectomy or induces distinct 
processes will require further study. Moreover, 
the regenerative mechanisms associated with 
PVL alone will need clarification to appreciate 
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how Ihh signaling accelerates ALPPS-
associated liver growth. However, our findings 
are consistent with the view that stellate cells 
are the main conveners of hedgehog signaling 
associated with ALPPS-triggered regeneration, 
akin to early regenerative responses after other 
liver insults.  
The general involvement of hedgehog activity 
in various processes related to tissue 
remodeling, such as in response to growth or 
injury [14], portray Ihh signaling a plausible 
mechanism to contribute to ALPPS-enforced 
regeneration. Currently it is unclear how 
ALPPS may induce the Ihh-dependent 
cascade. Combining PVL with LLLx has no 
accelerating effect, because for ALPPS, the 
left lateral lobe is being occluded anyway 
before its resection. On the other hand, 
transection is the key factor differentiating 
ALPPS from PVL and would be an obvious 
candidate. Liver injury induced by transection 
conceivably might induce a repair response 
including Ihh secretion. Plasma Ihh levels did 
rise over time after transection only, however 
to much lower levels than following ALPPS, 
and without upregulating Ihh mRNA (Fig. 2). 
Therefore, transection is not the cause of active 
Ihh production seen after ALPPS (but may 
contribute perhaps by causing release of 
matrix-bound Ihh). Rather, the combination of 
PVL with transection appears to elicit a 
synergistic effect, with ALPPS triggering 
much higher Ihh plasma levels than the sum of 
Ihh seen after each procedure alone (Fig. 2). 
How the combination of occlusion and injury 
is leading to Ihh secretion will require further 
study. Injury, however, seems to be an 
important component, and even injection alone 
had some accelerating effect on PVL-induced 
regeneration (see PVL+PBS/Ihh versus 
PVL/ALPPS, Fig. 4A). Ihh signaling indeed is 
the first molecular insight into ALPPS-related 
mechanisms, and much more work will be 
needed to clarify triggers, contributing sources, 
and the various cellular crosstalks that underlie 
Ihh-dependent acceleration of liver 
regeneration in response to ALPPS.  
The powerful promotion of regenerative speed 
seen in PVL mice after Ihh injection suggests 
therapeutic potential for this protein. In support 
of such potential, we observed early IHH 
elevations in ALPPS patients. Future studies 
should address specific clinical situations 
where hedgehog activation might be of benefit. 
At present, IHH may be of value for liver 
patients in need of but unsuitable - e.g. due to a 
critical health state - for major surgery such as 
ALPPS step 1. Given that the usual indication 
for resections is malignancy, the well-known 
cancer-promoting activities of hedgehog 
signaling [25] will have to be carefully 
balanced against the benefits for individual 
patients. In this regard, a single therapeutic 
IHH injection might have a small enough 
impact on neoplasia to be applied to patients at 
high risk of death due to unresectable disease. 
However, the tumorigenic risks associated 
with an IHH bolus are currently unknown and 
will need meticulous assessment in the settings 
of PVL. Of note, recent (but still limited) 
numbers suggests that ALPPS - as we show 
inducing IHH in patients - is not associated 
with higher recurrence rates than PVL [7] 
despite existing concerns [26]. Clearly, the 
tumorigenic potential of an IHH bolus in the 
settings of PVL will need to be addressed 
experimentally.  
In summary, we report the first insight into the 
molecular principles underlying the 
acceleration of liver regeneration through 
ALPPS. The elevations in circulating Ihh early 
after ALPPS are both sufficient to accelerate 
compensatory liver growth following 
occlusion and required for ALPPS to develop 
full effect. Our findings highlight the 
dependency of ALPPS on humoral factors and 
provide a basis for a pharmaceutical promotion 
of compensatory liver growth in the clinic. The 
identification of Ihh as an accelerating factor is 
a first step in deciphering the mechanistic 
processes underlying ALPPS and in exploring 
according therapeutics for the expanded 
application of liver surgery. 
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Figures 
Figure 1. Acceleration of compensatory liver growth through ALPPS. (A) ALPPS surgery in mouse 
and its effects on liver re-growth. Gray shading indicates occluded liver parts following PVL. The 
black line indicates the transection step, and the yellow line the LLLx step. Percent body weight and 
liver weight regain (expressed as percent functional-liver-remnant-to-body-weight-ratio) after surgery 
are shown in the left and right graph, respectively. (B) H&E, Ki67, and pH3 staining of liver after 
surgery. Graphs show counts of hepatocytes positive for Ki67 or bold pH3. Histology (H&E) for sham 
was consistent over time. (C) Hepatic gene expression of Ccnd1, Ccne1, Ccna2, Ccnb1, and Ccnb2 
after surgery. (D) Hepatic protein expression (normalized to Gapdh) of p21 after surgery. N = 6/group. 
t-test, *p <0.05, ** p <0.01. ***p <0.001. Significances refer to ALPPS vs. PVL comparison unless 
otherwise stated.  
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Figure 2. Ihh induction after ALPPS. (A) Hepatic gene expression profiles derived from RNA 
sequencing at 4h after surgery. Note the unique ALPPS profile. (B) Visual presentation (Venny 2.0) of 
overlaps between top dysregulated pathways (fold change ≥ 2, p >0.05) derived from MetaCore 
pathway analysis of 4h-expression profiles. (C) Venny visualization of dysregulated genes (fold 
change ≥ 4, p  >0.05) in two-pair comparisons. N = 3/group for expression profiling. (D) Hepatic Ihh 
gene expression, hepatic Ihh protein expression (normalized to Gapdh), and plasma Ihh protein levels 
(ELISA) after surgery. (E) Ihh immunohistochemistry. Note the similar staining patterns across all 
groups. N = 6/group. t-test, *p <0.05, **p <0.01, ***p <0.001.  
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Figure 3. Hedgehog pathway components after surgery. (A) Gene expression for Hhip1, Ptch1, Smo, 
Gli1, and Gli2. N = 6/group. (B) Cytosolic and nuclear protein levels (normalized to -tubulin and 
lamin B1, respectively; see immunoblots in Supplementary Fig. 2) of Gli1 and Gli2. N = 6/group. 
Right panels: immunofluorescence for hepatic Gli1. Note for ALPPS liver the nuclear staining 
predominantly in hepatocytes. At 8h, Gli1 expression was more prominent in parenchymal than non-
parenchymal cells for ALPPS relative to transection, PVL and sham. In sham liver, cytoplasmic 
staining was increased in non-parenchymal cells at 8h relative to 4h. t-test, *p <0.05, **p <0.01, ***p 
<0.001 for PVL vs ALPPS unless indicated otherwise. ALPPS, associated liver partition and portal 
vein ligation for staged hepatectomy; PVL, portal vein ligation; Ts, transection. 
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Figure 4. Effects of recombinant Ihh on PVL-induced liver regeneration. (A) Percent body weight and 
functional-liver-remnant-to-body-weight-ratio after PVL-Ihh, PVL-PBS, ALPPS, PVL and transection 
are shown in the left and right graph, respectively. (B) Corresponding H&E, Ki67, and pH3 staining of 
liver. Graphs show counts of hepatocytes positive for Ki67 or pH3. Note the increases in bold pH3-
positive nuclei 12h after PVL-Ihh. (C) Hepatic gene expression of Hhip, Gli1 Gli2, and Ccnd1 after 
PVL plus PBS or Ihh. (D) Cytosolic and nuclear protein levels (normalized to -tubulin and lamin B1, 
respectively) of Gli1 and Gli2. (E) Quantified cyclin D1 immunoblots. N = 6/group. t-test, *p <0.05, 
**p <0.01, ***p <0.001 for PVL-PBS vs PVL-Ihh. 
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Figure 5. Effects of neutralizing Ihh antibody on ALPPS-induced liver regeneration. (A) Percent body 
weight and functional-liver-remnant-to-body-weight-ratio after ALPPS-αIhh antibody, ALPPS-PBS, 
ALPPS, PVL, and transection. (B) Corresponding H&E, Ki67, and pH3 staining of liver, with graphs 
showing Ki67 or pH3 counts. (C) Hepatic gene expression of Hhip, Gli1, Gli2, and Ccnd1 after 
ALPPS plus PBS or αIhh antibody. (D) Cytosolic and nuclear protein levels of Gli1 and Gli2. (E) 
Quantified cyclin D1 immunoblots. t-test, *p <0.05, **p <0.01, ***p <0.001 for ALPPS-PBS vs 
ALPPS-αIhh 
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Figure 6. Human IHH levels in clinical material. Plasma from ALPPS patients was available at 0h 
(baseline), 2 h, 24 h, and 48 h after PVL and transection.  IHH levels were assessed by ELISA.  
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Supplementary Materials 
Supplementary Tables 
Table S1. Taqman gene expression assays 
gene name Applied Biosystems order no.  
Ccna1 Mm00438064_m1 
Ccnb1 Mm00838401_m1 
Ccnb2 Mm01171453_m1 
Ccnd1 Mm00432359_m1 
Ccne1 Mm00432367_m1 
Gli1 Mm00494654_m1 
Gli2 Mm01293117_m1 
Hhip Mm00469580_m1 
Ihh Mm00439613_m1 
Ptch1 Mm00436026_m1 
Smo Mm01162710_m1 
18S rRNA  Control reagents 
 
Table S2. Antibodies 
Antigene Company (order no.) Dilution 
Ki67 Abcam, Cambridge, UK (ab16667) 1:200 (IHC) 
pH3 Millipore, Schaffhausen, CH (06-570) 1:500 (IHC) 
Ihh Abcam, Cambridge, UK (ab39634) 1:500 (IHC) 
secondary  Thermo Fischer, Rockford, IL, USA (62-9511) 1:50 (IF) 
Gli1 R&D, Zug, CH (Mab3324) 
1:50 (IF) 
1:5000 (WB) 
Gli2 Abcam, Cambridge, UK (ab26056)  1:500 (WB) 
cyclin D Abcam, Cambridge, UK (ab16663) 
1:100 (IHC) 
1:100 (WB) 
lamin B1 Santa Cruz, CA USA (sc-377001) 1:500 (WB) 
-tubulin Cell Signaling, MA USA (2128S) 1:1000 (WB) 
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Table S3. Patient information 
Patient Age Gender Weight Indication 
Co- 
morbidity 
Histology 
Increase 
in FLR 
volume* 
Postoperative 
Complications 
 
Postoperative 
Complication 
Score (CCI) 
1 55 female 54 kg 
 
synchronous 
liver 
metastases of 
adeno-
carcinoma of 
the rectum 
none 
slight 
pericellular 
fibrosis,  
no higher 
fibrosis,  
no steatosis 
20.5% 
wound dehiscence, 
pneumothory, 
ohylothorax, 
electrolyte disorder, 
renal insufficiency 
55.7 
2 57 male 91 kg 
 
synchronous 
liver 
metastases of 
adeno-
carcinoma of 
the rectum 
none 
Macro-
steatosis  
ca. 20%,  
no fibrosis 
 
3.5% VAC, antibiotics 29.6 
3 35 female 61 kg 
 
synchronous 
liver 
metastases of 
adeno-
carcinoma of 
the rectum 
cancer of 
right breast 
none (slight 
pericellular 
fibrosis in 1 
biopsy) 
 
29.3% none 0 
4 37 female 65 kg 
 
synchronous 
liver 
metastases of 
adeno-
carcinoma of 
the sigmoid 
colon 
none 
minimal 
pericellular 
fibrosis 
without 
bridging 
 
18.2% 
blood transfusion 
 22.6 
5 47 male 82 kg 
 
metachronous 
liver 
metastases of 
adeno-
carcinoma of 
the rectum 
none 
macro-
steatosis ca. 
30% 
 
22.5% 
bed side wound 
opening, antipyretics 
 
8.7 
6 55 male 105 kg 
hepatocellular 
carcinoma 
liver 
cirrhosis, 
child-pugh 
score A due 
to chronic 
hepatitis C, 
genotype 1B 
moderate 
inflammatory 
activity (A2), 
fibrosis: 
metavir-
stage F4 
 
13.9% none 0 
*represents future liver remnant (FLR) volume before step 2 minus liver volume before step 1 of 
ALPPS 
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Table S4. Differentially expressed pathways 
 LLLx vs sham P-value FDR 
1 Cytoskeleton remodeling_TGF, WNT, & cytoskeletal remodeling 4.758e-31 4.292e-28 
2 Cytoskeleton remodeling_Cytoskeleton remodeling 1.666e-25 7.514e-23 
3 Cell adhesion_Chemokines and adhesion 1.558e-19 3.512e-17 
4 Development_Regulation of epithelial-to-mesenchymal transition  3.576e-18 6.451e-16 
5 Development_EGFR signaling pathway 8.560e-17 1.103e-14 
6 Development_TGF-beta receptor signaling 2.209e-16 2.490e-14 
7 Transcription_Sin3 and NuRD in transcription regulation 4.431e-16 4.441e-14 
8 Transport_Clathrin-coated vesicle cycle 1.003e-15 9.051e-14 
9 Signal transduction_JNK pathway 2.222e-15 1.822e-13 
10 Cell cycle_Influence of Ras and Rho proteins on G1/S Transition 1.462e-14 8.792e-13 
 PVL vs sham P-value FDR 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 9.008e-30 8.12e-27 
2 Cytoskeleton remodeling_Cytoskeleton remodeling 1.435e-25 6.471e-23 
3 Cell adhesion_Chemokines and adhesion 1.366e-19 3.081e-17 
4 Development_Regulation of epithelial-to-mesenchymal transition  3.244e-18 5.851e-16 
5 Development_EGFR signaling pathway 7.742e-17 9.977e-15 
6 Transcription_Sin3 and NuRD in transcription regulation 2.780e-16 3.135e-14 
7 Transport_Clathrin-coated vesicle cycle 9.103e-16 8.211e-14 
8 Cell cycle_Influence of Ras and Rho proteins on G1/S Transition 1.351e-14 8.703e-13 
9 Immune response_IL-18 signaling 1.742e-14 1.039e-12 
10 Immune response_IL-1 signaling pathway 2.295e-14 1.150e-12 
 transection vs sham P-value FDR 
1 Cytoskeleton remodeling_TGF, WNT, and cytoskeletal remodeling 6.753e-27 6.092e-17 
2 Cytoskeleton remodeling_Cytoskeleton remodeling 1.110e-25 5.005e-23 
3 Cell adhesion_Chemokines and adhesion 1.091e-19 2.459e-17 
4 Development_Regulation of epithelial-to-mesenchymal transition  2.743e-18 4.948e-16 
5 Development_EGFR signaling pathway 6.516e-16 8.396e-15 
6 Transcription_Sin3 and NuRD in transcription regulation 3.634e-16 4.097e-14 
7 Transport_Clathrin-coated vesicle cycle 7.701e-16 7.718e-14 
8 Transport_Clathrin-coated vesicle cycle 1.179e-14 7.596e-13 
9 Immune response_IL-18 signaling 1.506e-14 8.856e-13 
10 Immune response_IL-1 signaling pathway 2.034e-14 1.079e-12 
 ALPPS vs sham P-value FDR 
1 Cytoskeleton remodeling_TGF, WNT, and cytoskeletal remodeling 7.990e-30 7.207e-27 
2 Cytoskeleton remodeling_Cytoskeleton remodeling 1.289e-25 5.815e-23 
3 Cell adhesion_Chemokines and adhesion 1.244e-19 2.805e-17 
4 Development_Regulation of epithelial-to-mesenchymal transition  5.850e-17 8.795e-15 
5 Development_EGFR signaling pathway 7.206e-17 9.286e-15 
6 Transcription_Sin3 and NuRD in transcription regulation 3.910e-16 4.408e-14 
7 Transport_Clathrin-coated vesicle cycle 8.491e-16 8.510e-14 
8 Cell cycle_influence of Ras and Rho proteins on G1/S Transition 1.276e-14 8.223e-13 
9 Development_TGF-beta-dependent induction of EMT via MAPK 5.998e-14 3.182e-12 
10 Transcription_Sirtuin6 regulation and functions 1.169e-13 5.479e-12 
 
List of Metacore pathways used for Venny diagrams displaying ALPPS specific pathways. The Ihh 
gene was included in the the sirtuin 6 pathway (ALPPS vs. sham, no. 10. FDR, false discovery rate. 
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Table S5. Differentially expressed genes 
gene log2ratio FDR 
Dmbt1 13.7 4.39e-06 
Atp2a1 8.2 1.01e-06 
Akr1b7 7.8 1.80e-73 
Cyp11b1 6.5 2.23e-05 
Slc4a9 6.3 2.95e-06 
Ihh 6.0 2.96e-30 
Ly6k 5.8 9.12e-05 
Sprr1a 5.4 8.79e-19 
Fscn2 5.2 2.20e-13 
Pax9 5.2 0.0004318 
Tac1 5.2 2.20e-13 
Otoa 5.1 0.00187 
Slfn10-ps 4.9 0.001714 
Bmp8b 4.8 1.77e-12 
Ly6b 4.8 6.88e-18 
Nes 4.8 8.01e-40 
Fhl3 4.7 2.94e-19 
Cd14 4.6 1.07e-09 
Tubb3 4.5 1.78e-06 
Sprr2a2 4.4 0.0001004 
Mrap 4.3 1.07e-30 
Ralgds 4.3 5.34e-25 
Sphk1 4.3 2.13e-20 
Ier3 4.2 2.13e-20 
Krt8 4.2 2.84e-27 
Duox2 4.1 0.03272 
Nefm 4.1 3.68e-05 
Tnfrsf12a 4.1 1.86e-24 
Barx2 4.0 7.75e-07 
Col12a1 4.0 9.99e-30 
Krt18 4.0 3.49e-25 
Mmp24 4.0 1.99e-09 
Gm15348 -4.0 2.25e-07 
Ciart -4.1 4.26e-16 
N4bp2l1 -4.1 1.57e-26 
Gbp2b -4.3 3.50e-06 
Hist2h3c1 -4.3 5.58e-12 
Gas 1 -4.5 1.74e-11 
Gm17597 -4.6 0.01507 
Hist2h3c2 -4.6 2.24e-08 
Zfp936 -4.6 0.01401 
Fbxo40 -4.7 0.01297 
B4galnt3 -4.9 1.64e-06 
Kif14 -4.9 0.004497 
Ackr4 -5.0 0.006229 
B230217C12Rik -5.4 0.000462 
3222401L13Rik -5.4 0.0006822 
Pif1 -5.5 0.0002963 
Gm17435 -5.6 0.0001665 
 
50 unique genes to ALPPS identified through Metacore (filter criteria: fold change ≥4, P≤0.05) 
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Supplementary Figures 
 
Figure S1. Percentage liver weight gain after ALPPS versus hepatectomy. 
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Supplementary Figure 1. Percentage liver weight gain after ALPPS compared to hepatectomy and 
the surgical controls. The weight of the remnant at surgery was set to one, enabling the comparison of 
ALPPS and PVL (10% remnant) with partial hepatectomy (30% remnant).   
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Figure S2. Immunoblots for protein quantifications  
 
Supplementary Figure 2. Representative immunoblot bands corresponding to quantification graphs 
shown in the main figures 1, 3, 4 and 5. For quantifications, at least 6 samples/group were included.    
  
Figure 1
Figure 3
Figure 4
Figure 5
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Figure S3. Differentially expressed genes following surgery over time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Full heatmap of RNA deep sequencing data representing gene expression 
profiles at 0.5h, 1h, 4h, 8h, and 12h following ALPPS and control surgeries. Performed on the 
Illumina HiSeq 2500 by the Functional Genomic Center Zurich (FGCZ). Raw data was analyzed by 
EdgeR two-group analysis. 
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Figure S4. Shh/Dhh RNA sequencing data and Shh plasma levels.  
 
 
 
Supplementary Figure 4. Top: Shh and Dhh expression data derived from the RNA sequencing 
screen. No ALPPS-specific changes were detectable. Bottom: Shh plasma protein levels (ELISA) 
following surgical procedurs including standard hepatectomy. No ALPPS-specific changes were 
apparent.  
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Figure S5. Immunohistochemistry for Ihh. 
 
 
 
 
 
 
 
 
Supplementary Figure 5. Immunostainings for Ihh of liver 4h after ALPPS surgery. Ihh expression is 
observed in non-parenchymal cells, including cells with typical stellate morphology. At 4h after 
ALPPS, hepatic mRNA and plasma Ihh levels peak, suggesting Ihh is sourced from stellate cells and 
not hepatocytes.  
  
Ihh  4h post ALPPS 32x Ihh  4h post ALPPS 64x Ihh  4h post ALPPS 64x 
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Figure S6. Immunohistochemistry for cyclin D1 on liver post surgery 
 
Supplementary Figure 6. Representative immunostainings for cyclin D1 on liver after ALPPS, PVL, 
transection and sham operation. Note the peak in nuclear positivity at 8h after ALPPS.  
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Figure S7. Immunohistochemistry for cyclin D1 on liver after Ihh gain or loss treatment. 
 
Supplementary Figure 7. Representative immunostainings for cyclin D1 on liver after treatment of 
PVL mice with Ihh/PBS (upper panels) or after treatment of ALPPS mice with Ihh/PBS (lower 
panels).  
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Figure S8. Estimation of cellular hypertrophy after ALPPS. 
 
 
 
 
 
Supplementary Figure 8. Cellular hypertrophy following ALPPS, PVL, Ts and sham. Hypertrophy 
was estimated by counting hepatocyte nuclei per area, with higher counts correlating to smaller cell 
size. At 4h (*P<0.05, ALPPS vs PVL) and 8h (***P<0.001, ALPPS vs PVL), ALPPS liver displayed 
significantly elevated nuclear counts, pointing to a smaller cell size relative to PVL. At 12h however, 
counts were similar for all procedures. Therefore, cellular hypertrophy seems not to contribute to the 
increases in liver weight seen early after ALPPS. Five random visual fields (20x magnification) were 
counted per sample on H&E stains in a blinded way.  
 
Figure S9: Hgf, Egf, and Il6 expression after surgery. 
 
 
 
 
 
 
Supplementary Figure 9. Gene expression of classic promoters of liver regeneration after ALPPS 
and control surgeries. Gene expression was derived from RNA sequencing data. Tnfa, another classic 
regeneration molecule, was undetectable in the data set. n=3/group.  
 
 
* *** 
Hgf Egf IL-6 
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Abstract  
Background & Aims: To improve outcomes of two-staged hepatectomies for large/multiple liver 
tumors, portal vein ligation (PVL) has been combined with parenchymal transection (coined ALPPS; 
Associated Liver Partition and Portal vein ligation for Staged hepatectomy) to greatly accelerate liver 
regeneration. In a novel ALPPS mouse model, we have reported paracrine Indian hedgehog (IHH) 
signaling from stellate cells as an early contributor to augmented regeneration. Here, we sought to 
identify upstream regulators of IHH.  
Methods: ALPPS in mice was compared against PVL and additional control surgeries. Potential IHH 
regulators were identified through in silico mining of transcriptomic data. JNK1 activity was reduced 
through SP600125 to evaluate its effects on IHH signaling. Recombinant IHH was injected after JNK 
diminution to substantiate their relationship during accelerated liver regeneration. 
Results: Mining linked Ihh to Mapk8. JNK1 upregulation after ALPPS was validated and preceded the 
IHH peak. On immunofluorescence, JNK1 and IHH co-localized in ASMA-positive non-parenchymal 
cells. Inhibition of JNK1 prior to ALPPS surgery reduced liver weight gain to PVL levels and was 
accompanied by downregulation of hepatocellular proliferation and the IHH-GLI1-CCND1 axis. In 
JNK1-inhibited mice, recombinant IHH restored ALPPS-like acceleration of regeneration and re-
elevated JNK1 activity, suggesting the presence of a positive IHH-JNK1 feedback loop.  
Conclusions: JNK1-mediated induction of IHH paracrine signaling from HSCs is essential for 
accelerated regeneration of parenchymal mass. The JNK1-IHH axis is a mechanism unique to ALPPS 
surgery and may point to therapeutic alternatives for patients with insufficient regenerative capacity.   
Keywords: compensatory hypertrophy; small-for-size syndrome; future liver remnant.           
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Introduction 
The unique ability of mammalian liver to 
regain mass after tissue loss has revolutionized 
the treatment and cure of many patients with 
liver tumors. However, there are limitations to 
effective regeneration, as hepatic failure may 
develop after extensive liver resection. This 
entity, known as the small-for-size syndrome 
(SFSS), results from an insufficient functional 
volume of the liver remnant and remains the 
most frequent cause of death due to liver 
surgery [1,2]. Two-staged hepatectomies were 
introduced to reduce the SFSS risk. Typically, 
the portal vein draining the part of the liver 
containing the tumor is occluded (step 1), 
causing growth of the contralateral liver part 
(defined as the future remnant liver (FRL)); 
when the FRL has gained sufficient functional 
volume, step 2 (resection of the diseased part) 
is performed [2,3]. Nevertheless, in some cases 
regeneration is still insufficient, or the 
considerable time period between step 1 and 2 
allows for further progression of the disease 
[4,5]. To additionally reduce the risk of SFSS 
in patients with large or multiple liver tumors, 
ALPPS (Associated Liver Partition and Portal 
vein ligation for Staged hepatectomy: the 
combination of portal vein ligation with 
parenchymal transection) has been showcased 
as a procedure that induces accelerated liver 
regeneration and greatly reduces the interval 
between steps, allowing treatment of patients 
otherwise deemed as unresectable [6,7]. This 
procedure, introduced about five years ago, has 
gained sustained acceptance with more than 
1000 cases included in an international registry 
(http://www.alpps.net/?q=registry).  
Although there have been several clinical 
studies evaluating ALPPS in patients, reports 
on the molecular mechanisms underlying the 
regenerative acceleration following ALPPS-
step 1 remain scarce. Several components 
known to be necessary for liver regeneration 
after partial hepatectomy have likewise been 
associated with accelerated regeneration. In 
rodent models, IL-6 and TNFα - established 
mediators of liver regeneration - have been 
found upregulated in ALPPS at the mRNA and 
protein level. Similarly, protein expression of 
STAT3, RELA, and YAP1 – known 
transcription factors in the regenerating liver - 
were elevated after ALPPS step 1 [8,9]. 
Furthermore, hypoxia has recently been shown 
to be an important driver of normal 
regeneration through HIF2α, with preliminary 
studies pointing to the importance of hypoxia 
also in ALPPS [10,11]. In human ALPPS 
tissues, IL-6 and TNFα have been validated on 
the mRNA level [12]. However, none of these 
molecules seems to be unique to the ALPPS-
induced acceleration of regeneration.  
We have developed a mouse model of ALPPS 
and documented the release of serum factors 
that can accelerate regeneration in mice 
following portal vein ligation (PVL) only to 
levels seen after the complete ALPPS-step 1 
procedure [12]. These findings suggest that 
humoral factors must play essential roles in the 
early instigation of accelerated regeneration. 
With this mouse model, we established that the 
secretion of Indian Hedgehog (IHH) from 
hepatic stellate cells (HSCs) was necessary for 
the early activation and progression of 
accelerated regeneration [13]. Although 
hedgehog signaling has previously been 
reported to be required for regeneration after 
hepatectomy, the early elevations in serum 
IHH were unique to ALPPS, and not observed 
following hepatectomy or other surgeries [13].  
Hedgehog activity is barely detectable in 
healthy adult liver. Upon hepatectomy, 
however, hepatocytes begin to proliferate and 
HSCs undergo differentiation into 
myofibroblastic and fibrogenic states [14,15]. 
Furthermore, there is increasing evidence that 
morphogenic signals - such as the hedgehog 
pathway - are mediators of the myofibroblastic 
HSC switch. When blocking or knocking out 
Smo, the receptor for hedgehog ligands, HSCs 
do not acquire myofibroblastic traits, and 
subsequent hepatocyte regeneration is inhibited 
[16,17,18].  
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Given the specific secretion of IHH after 
ALPPS, this study sought to identify upstream 
regulators of the ligand as to establish the role 
of IHH in ALPPS. On the other hand, 
expanding on the networks that act to 
accelerate regeneration after ALPPS may 
provide insight into new therapeutics for the 
pharmacological promotion of regeneration in 
clinical settings.   
Materials and Methods 
Animals  
All animal experiments were performed in 
accordance with Swiss Federal Animal 
Regulations and approved by the Veterinary 
Office of Zurich. Male C57Bl/6 mice (Envigo, 
Horst, NL) aged 10-12 weeks kept on a 12-
hour day/night cycle with free access to food 
and water were used.  
Animal surgery and treatment 
To mimic human ALPPS surgery in mice, 90% 
PVL was performed leaving a 10% functional 
remnant consisting of the left and a part of the 
right middle lobe. Then, a partial 80% 
transection was done through the middle lobe 
along the demarcation line of the 
occluded/non-occluded parenchyme. The left 
lateral lobe (LLL, 25% of liver volume) was 
also resected to simulate the cleaning of the 
liver from smaller tumors as often done in 
human ALPPS. Details on isoflurane 
anesthesia, buprenorphine analgesia, ALPPS 
procedures, and the control operations (90% 
PVL, 80% transection, and sham laparotomy) 
have been described [12,13]. After surgery, 
animals were allowed to recover on a warming 
pad in a separate cage until completely 
conscious. Animals were weighed before 
surgery and at sacrifice, where weight of 
resected and remnant liver was recorded. 
Tissue was formalin fixed or snap frozen, 
while plasma was stored at -80°C for analysis.  
SP600125 (0.016mg/gram BW, InVivoGen, 
tlrl-sp60 Toulouse, FR), a specific JNK 
inhibitor, or DMSO in oil was injected I.P. one 
hour before operation. Recombinant Ihh (200 
ng/kg, 160l final volume; R&D, 1705-HH-
025/CF Minneapolis, MN) or PBS was 
injected into the vena cava right after 
operation. Ihh antibody (4ug/kg, 160l final 
volume; R&D MAB8048) or PBS was injected 
via tail vein one hour before operation.  
Liver regeneration  
Liver regeneration was assessed by the 
percentage of functional-liver-remnant-to-body 
weight ratio (FLR/BW) derived from six 
animals per group and time point.  
Quantitative real-time PCR  
Total RNA was extracted from 50 mg of tissue 
using Trizol reagent following provided 
instructions (Invitrogen, Basel, Switzerland). 
RNA quality/quantity was spectrometrically 
assessed. qPCR was performed with two 
replicates/sample on cDNA (Thermo Script 
reverse transcription PCR System, Invitrogen) 
using an ABI Prism 7500 Sequence Detector 
system (PE Applied Biosystems Rotkreuz, 
Switzerland). Taqman gene expression assays 
from Applied Biosystems are listed in 
Supplementary Table 1. Results represent 
mean fold induction (2
-ΔCt
) ±SD relative to the 
normalization control 18S rRNA [19].  
Histological Examination 
Archived liver sections (3 μm) were stained 
(antibodies in Supplementary Table 2) using 
the Dako Autostainer Link48 Instrument and 
the iView DAB kit (Dako Denmark A/S). 
Quantification of Ki67-, bold pH3- [19], cyclin 
D-, and pJNK-positive hepatocytes was 
achieved by blinded manual counting in 10 
random visual fields (20x). For 
immunofluorescence, GLI1 antibody (R&D, 
Zug, Switzerland) was detected using an Alexa 
Fluor 488-conjugated anti-rat secondary 
antibody (Invitrogen, Zug, Switzerland). For 
co-immunofluorescence, primary antibodies 
are listed in Supplementary Table 2 and rabbit- 
and mouse-specific Alexa Fluor 488 and 594-
conjugated secondary antibodies were used 
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respectively. Representative slides of five 
biological samples per group are shown. 
In-silico analysis 
RNA sequencing raw data of the accession 
number PRJEB15593 in the European 
Nucleotide Archive (ENA) was used for in-
silico analysis via the online String Database 
(string-db.org). 
Protein analysis 
Western blotting was performed as described 
[19]. Antibodies are listed in Supplementary 
Table 2. NE-PER Nuclear and Cytoplasmic 
Extraction reagents (Thermo Fisher Scientific, 
Waltham, MA, PK207589) were used to 
isolate subcellular fractions, with their 
separation ascertained through β-tubulin 
(cytoplasmic) and lamin B1 (nuclear) blotting. 
IHH protein levels were measured by ELISA 
(mouse IHH: Cusabio, CSB-E16517m).  
Statistical Analysis.  
Data are expressed as mean ±SD. Differences 
between groups (n=6/group unless for 
expression profiling with n=3/group and for 
histological counting with n=5/group) were 
determined using unpaired, two-tailed t tests 
assuming unequal variance via GraphPad 
Prism v4.0 (GraphPad, San Diego CA), with 
significance set at P<0.05. Analyses were 
performed in a blinded way.   
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Results 
Early upregulation of JNK1 in accelerated 
liver regeneration 
To identify potential upstream regulators of the 
IHH pathway in accelerated liver regeneration 
we conducted an in-silico analysis of our RNA 
sequencing data sets derived from livers at 
early times after ALPPS, PVL, transection, or 
sham surgery [13].  Genes that discriminated 
ALPPS liver from other surgeries were 
included. Using string.db.org, Mapk8 was text-
mined to be linked to Ihh and Ccnd1 of the 
hedgehog pathway (Fig 1A). Our RNA seq 
data suggested Mapk8 upregulation at early 
times after ALPPS, which we confirmed by 
qPCR in a new set of animals subjected to the 
different surgeries (Figure 1B). The 
deregulation of JNK1 was further confirmed 
on the protein level. pJNK1, the active form of 
JNK phosphorylated on Thr183 and Tyr185, 
was upregulated as early as 1 hour after 
ALPPS (Fig 1C). Therefore, JNK1 activation 
through ALPPS surgery precedes the serum 
IHH peak that we have previously observed at 
4h post operation [13]. From these findings, 
we hypothesized that JNK1 plays a part in 
accelerated liver regeneration as a potential 
instigator of IHH signaling.  
Ihh and JNK1 are present in activated non-
parenchymal cells  
To establish an association between JNK1 and 
IHH signaling, we stained liver sections 4h 
after  operation (ALPPS, PVL, transection, and 
sham) for IHH, ASMA (a marker of activated 
hepatic stellate cells [20,21]), and pJNK1. 
Non-parenchymal cells were positive for all 
the three proteins across samples 
(Supplementary Fig 1), suggesting pJNK1 and 
IHH may interact in stellate cells to accelerate 
regeneration. To assess localization of IHH 
and pJNK1 in activated hepatic stellate cells, 
we applied immunofluorescence (Fig 2A, 
Supplementary Fig 2) to paraffin-embedded 
liver sections after operation. pJNK1 co-
localized with both αSMA and IHH, indicating 
their simultaneous presence in activated 
stellate cells.  
JNK1 is thought to preferentially act in nuclei 
when phosphorylated [22,23]. To substantiate 
an JNK-IHH association, we prepared 
cytosolic and nuclear fractions from liver at 4h 
and 24h post surgery and assessed protein 
levels of pJNK1, the IHH downstream effector 
and transcription factor GLI1, and its 
proliferative target CCND1 [13]. Indeed, the 
nuclear increases in pJNK were paralleled by 
increases in GLI1, while nuclear levels of total 
JNK1 and GLI2 remained unchanged 
(Supplementary Fig 3). CCND1 was 
significantly elevated at 24h in nuclear 
fractions (Figure 2C), fitting its delayed 
induction seen on immunoblots 8h after 
ALPPS as previously reported [13]. On the 
other hand, a non-significant elevation in 
CCND1-positive hepatocyte nuclei was noted 
on immunohistochemistry at 4h post ALPPS, 
and was accompanied with increases in 
proliferative marker (Ki67, pH3) counts. 
Likewise, the elevated nuclear CCND1 
positivity correlated with Ki67/pH3 increases 
at 24h post ALPPS (Figure 2C, Supplementary 
Fig 4).  
These findings associate JNK1 activation with 
both the induction of IHH signaling and the 
promotion of proliferation following ALPPS. 
Therefore, JNK1 may foster regeneration in 
ALPPS by causing release of IHH from stellate 
cells to induce paracrine proliferation of 
hepatocytes via GLI1-CCND1.  
[13,22,24,25,26]. 
Reduction of JNK1 activity in ALPPS-treated 
mice abolishes regenerative acceleration  
If the elevated activity of JNK1 after ALPPS is 
promoting acceleration of regeneration, 
inhibiting JNK should reduce the ALPPS 
effects. To decrease JNK1 activity, we chose 
SP600125, a specific JNK inhibitor that has 
been widely used in liver regeneration studies 
due to its specificity and ease of application 
[27,28]. SP600125 was injected 1h prior to 
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ALPPS surgery, and the assessment of pJNK1 
levels in nuclear fractions confirmed a partial 
inhibition of the protein, with pJNK1 declining 
to levels seen in mice 4h after PVL (Fig 3A, 
Supplementary Fig 5).  
DMSO vehicle injections had no significant 
impact on body and liver weight after ALPPS, 
although DMSO seemed to reduce the ALPPS 
effects slightly. In contrast, SP600125 
significantly reduced the FLR/BW down to 
levels seen after PVL (Figure 3B). Congruent 
changes were observed for the proliferative 
markers Ki67 and pH3 in SP600125-treated 
animals (Figure 3C, Supplementary Figure 6). 
We conclude that partial JNK inhibition prior 
to ALPPS surgery reduces the regenerative 
speed to levels comparable to those after PVL. 
Therefore, JNK1 is an important instigator of 
the ALPPS-specific acceleration of liver 
regeneration.  
The inhibition of JNK1 downregulates the 
IHH-GLI1-CCND1 axis in hedgehog 
signaling 
To determine whether JNK1 may act through 
IHH signaling, we assessed the IHH pathway 
components in ALPPS mice treated with 
SP6100125 or control DMSO injection.  
Following ALPPS, IHH protein levels peak in 
serum at 4h with little changes in the liver, 
consistent with the secretion of the ligand from 
stellate cells. The increases in serum IHH then 
promote GLI1 nuclear translocation, 
downregulation of the hedgehog inhibitor 
HHIP, and CCND1 upregulation from 4h 
onwards after ALPPS [13]. Treatment with 
SP600125 reduced both serum and hepatic 
levels of IHH 4h post ALPPS (Figure 4A), 
suggesting JNK1 inhibits production and/or 
release of the hedgehog ligand. Consistent with 
IHH downregulation, Gli1 expression was 
decreased at 4h and 24h (Figure 4B), while 
Hhip expression was increased by SP600125 
treatment at 4h after ALPPS (Figure 4C). 
Likewise, GLI1 protein and its target CCND1 
were downregulated in nuclear fractions of 
ALPPS liver at 4h and 24h compared to 
vehicle controls (Figure 4C). 
Immunohistochemistry confirmed the 
reductions in nuclear GLI1 and CCND1 
(Figure 4E-F, Supplementary Figure 9) with 
SP600125 treatment. No significant expression 
changes were observed for Ptch1, Smo, Gli2 
(Supplementary Figure 7) and nuclear GLI2 
(Supplementary Figure 8), all molecules the 
expression of which does not change following 
IHH stimulation in ALPPS [13]. These 
findings identify IHH signaling as a potential 
mediator of JNK1's ability to accelerate 
regeneration in ALPPS.  
Recombinant IHH rescues ALPPS-induced 
regeneration after JNK inhibition  
If JNK1 is promoting its accelerating effects 
through IHH signaling, restoring IHH levels in 
SP600125-treated liver should re-accelerate the 
regenerative response after ALPPS surgery.  
Mice were pretreated with SP600125, ALPPS-
operated, injected with recombinant ligand 
(rIHH), and compared to vehicle (DMSO & 
PBS)-treated ALPPS controls. When assessing 
body weight after all treatments, no differences 
were observed between the groups. In contrast, 
the FLR/BW was significantly elevated after 
ALPPS+SP6+rIHH compared to ALPPS+SP6 
(Figure 5A). Notably, DMSO/PBS injection on 
its own seemed to have some negative impact 
on ALPPS-regeneration. Nonetheless, liver 
weight was statistically similar for the 
ALPPS+DMSO+PBS and the 
ALPPS+SP6+rIHH groups (Figure 5A). 
Likewise, congruent changes were observed 
for the proliferative markers Ki67 and pH3 
(Figure 5B, Supplementary Figure 10). 
Therefore, rIHH can compensate for the 
inhibition of JNK1 during ALPPS-associated 
regeneration.  
Recombinant IHH re-instates hedgehog 
signaling and promotes JNK1 activity in 
SP600125-treated ALPPS liver  
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To further elucidate the relationship between 
JNK1 and IHH in ALPPS, we evaluated the 
levels of the individual pathway components. 
In SP600125-ALPPS-treated mice, rIHH 
increased Gli1 and decreased Hhip expression 
(Figure 6A), as well as promoted nuclear GLI1 
and CCND1 on immunoblots and 
immunochemistry (Figure 6B-D, 
Supplementary Figure 11). Again, Ptch, Smo, 
Gli2 (Supplementary Figure 12), and GLI2 
(Supplementary Figure 13) were not 
significantly affected. Intriguingly, when 
assessing JNK1, rIHH also increased the levels 
of nuclear JNK1 (Supplementary Figure 14) 
and of nuclear pJNK1 on both immunoblots 
(Figure 6E) and immunohistochemistry 
(Supplementary Figure 15). Therefore, IHH 
can increase the activity of JNK1 in ALPPS 
liver with partially inhibited JNK1, suggesting 
the presence of a positive feedback loop 
between JNK1 and IHH. Altogether, these 
findings establish IHH as a downstream 
effector of JNK1 in the acceleration of 
regeneration after ALPPS surgery.   
Discussion 
Liver regeneration is a complex molecular 
response unique in its ability to restore full 
function to the organ [29]. Many pathways 
have been identified to participate, such as 
signaling through the hedgehog pathway 
[18,28]. Nevertheless, liver regeneration does 
not occur in all patient scenarios, as liver 
failure ensues if the loss of functional tissue is 
too extensive [4]. With the introduction of 
ALPPS, the regenerative capacity has been 
extended and is expected to improve outcomes 
of two-staged hepatectomies in patients with 
marginal qualifications for resection. The 
unprecedented effect of ALPPS on liver 
recovery has provoked strong interest in the 
mechanisms underlying the acceleration of 
liver regeneration.   
Here, we demonstrate a hitherto undescribed 
interaction between JNK1 and IHH in stellate 
cells that acts to instigate accelerated liver 
regeneration early after ALPPS step 1 surgery. 
More specifically, we demonstrate that (i) 
JNK1 activation is associated with liver weight 
gain and precedes the upregulation of IHH-
GLI1-CCND1 signaling, (ii) partial inhibition 
of JNK1 reduces the rate of regeneration to 
that seen after PVL alone, along with 
congruent decreases in the IHH-GLI1-CCND1 
axis, and that (iii) recombinant IHH is 
sufficient to restore ALPPS regeneration in 
JNK1-inhibited mice.  
The alterations we observed following ALPPS, 
SP600125, and rIHH treatments were 
consistently reflected in GLI1-CCND1 nuclear 
levels and were strongly correlated with 
changes in proliferative markers as well as 
liver weight changes. On the other hand, 
molecules of the hedgehog pathway that were 
not affected through IHH (i.e. Ptch, Smo, 
GLI2) were also not altered through JNK1 
manipulation. Moreover, the changes in these 
hedgehog components were examined via 
PCR, Western blots as well as 
immunohistochemical approaches. Therefore, 
we can reliably conclude that JNK1 initiates 
the IHH-GLI1-CCND1 axis in accelerated 
regeneration.  
As a limitation to this study, pharmaceutical 
inhibition was employed to inhibit JNK1 
activity during our ALPPS experiments. 
Genetic knockout models may provide more 
clear-cut evidence; however, we decided for a 
pharmacological approach to reduce rather 
than block JNK activity, given the presence of 
low levels of pJNK1 also after PVL, the main 
ALPPS control surgery. Knockdown strategies 
may be an alternative, however SP600125 has 
been widely used in liver research including 
regeneration studies [22,23,26,28,32], 
rendering our study comparable to existing 
work on hepatic JNK.  
JNK1’s role after partial hepatectomy has been 
revealed by the observation that its inhibition 
blocks hepatocyte proliferation and liver 
regeneration [18,28,30]. JNK1 is activated 
within one hour after partial hepatectomy, 
leading to AP-1 activation, the promotion of 
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cyclin D1 expression, and hepatocellular G0-
G1 transition [22,30,31]. Interestingly, through 
studies in fibrosis, JNK1 was found to be 
involved in HSC activation, where it promotes 
ASMA expression and HSC proliferation 
[22,32]. The morphogenic hedgehog network 
likewise is recognized to be essential to liver 
regeneration and to promote expansion of 
activated HSCs [13,15,18,33]. However, 
whether JNK1 interacts with the Hedgehog 
pathway after partial hepatectomy is unknown. 
In analogy to regeneration after partial 
hepatectomy, we observed JNK1 upregulation 
one hour after ALPPS. Furthermore, JNK1 
localized to activated HSCs. The co-
localization of IHH and JNK1 in activated 
HSCs suggested a novel link between these 
two molecules, which we could demonstrate 
through SP600125 and recombinant IHH. 
Indeed, studies in skin cancer have revealed a 
link between JNK1 and the hedgehog pathway; 
there, JUN (the canonical JNK1 target) 
required synergistic interaction with GLI1 for 
full activation of downstream molecules [34]. 
Therefore, complex interactions appear to exist 
between JNK1 and hedgehog signaling.   
Unlike after partial hepatectomy, ALPPS did 
not increase the number of ASMA-positive 
cells, suggesting JNK1 activity does not 
promote HSC activation in these settings. 
While JNK1 clearly promotes regeneration 
after hepatectomy and ALPPS, the associated 
mechanisms seem to differ in some aspects. In 
ALPPS, the interaction between JNK1 and 
IHH is key in instigating accelerated 
regeneration. The extent to which IHH 
participates in regeneration after hepatectomy 
is unknown; however, the early, strong IHH 
secretion is unique after ALPPS, as plasma 
IHH increases occur at much later times and 
only at modest levels after resection [13,18]. 
On the other hand, we observed a statistically 
significant elevation of serum SHH at 4h after 
partial hepatectomy relative to ALPPS [13], 
suggesting SHH rather than IHH may be the 
hedgehog ligand relevant after resection. 
However, whether JNK1 is interacting with 
SHH after hepatectomy remains unknown. In 
mice, hepatectomy leads to little parenchymal 
injury, whereas in ALPPS, liver injury through 
parenchymal transection is preceded by 
ligation, which on its own induces regeneration 
through mechanisms that are ill-defined. 
Therefore, the divergent nature of the initial 
regenerative stimuli may underlie the timing 
and the set of interacting proteins/pathways 
that define the speed of regeneration after a 
given surgery.  
In this regard, an intriguing observation is that 
recombinant IHH not only restored accelerated 
regeneration in SP600125-treated mice, but in 
parallel increased the activity of the partially 
inhibited JNK1. These findings imply IHH 
enhances JNK1 activities in retrograde to 
promote its own secretion. While further 
evidence is required to establish such 
mechanisms, a positive feedback loop between 
JNK1 and IHH would provide an attractive 
explanation for the enhanced IHH secretion 
and the regenerative acceleration unique to 
ALPPS.  
Interestingly, both JNK and Hedgehog have 
prominent roles in the handling of liver injury. 
JNK is most notably activated by TNF-alpha, a 
cytokine involved in the pathophysiology of 
many types of liver injury, including viral 
hepatitis, alcoholic liver disease, and ischemia-
reperfusion injury. Activated JNK 
phosphorylates its targets (c-Jun, ATF-2, and 
JunD), and these transcription factors then 
activate genes that are involved in the 
regulation of inflammation, proliferation, and 
cell death. In the past few years, the use of 
JNK inhibitors has led to the understanding 
that the duration of JNK activation is critical 
for its pro-apoptotic effects in injury [35]. For 
example, Gunawan et al showed that transient 
blockade of JNK activity through SP600125 
was able to rescue mice from acetaminophen-
induced liver injury [36]. Similarly, the 
Hedgehog pathway has been identified to play 
a role in liver repair such as in regeneration 
and acute liver injury. In fibrogenic repair, 
production of Hedgehog ligands increases to 
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permit ligand-receptor interaction and 
activation of the Hedgehog signaling pathway, 
which is thought to be vital for the 
reconstitution of normal liver architecture [37]. 
In other tissues such as skin, reduced SHH 
production has been associated with the 
delayed healing seen in mice with diabetes, a 
condition closely related to liver disease [38]. 
Therefore, transient activation of JNK and 
Hedgehog pathways are important 
physiological processes fostering the repair of 
injured liver tissue. 
Chronic activation of JNK1, however, has been 
associated with the development and 
progression of hepatocellular carcinoma 
(HCC) [39]. Consistent JNK1 activity has been 
reported to predict a bad outcome in HCC, an 
aspect that perhaps relates to JNK1 activation 
secondary to chronic liver injury, an accepted 
cause of HCC. Although the pro-apoptotic 
function of JNK1 has been related to anti-
cancerous actions [40], recent evidence 
indicates a more complex situation, as JNK1 
may directly promote the repair of DNA 
breaks [39]. These observations suggest a 
disturbed balance between the removal or 
repair of damaged hepatocytes that underlies 
JNK1's association with a bad HCC outcome 
[39]. Indeed, a dual role of JNK1 in HCC has 
been postulated through animal models, where 
either its loss or its overactivation contribute to 
the development of malignancy [22]. 
Similarly, chronic hedgehog signaling has been 
linked to HCC. High levels of hedgehog 
components in HCC seem to maintain the 
proliferation of cancer stem cells, thereby 
contributing to HCC progression [41]. 
Likewise, liver diseases associated with 
chronic injury and an elevated HCC risk (i.e. 
nonalcoholic fatty liver disease) are 
accompanied by a chronic overactivation of the 
hedgehog pathway [42]. On the other hand, 
JNK1 and hedgehog activities remain 
associated with the successful healing of tissue 
injury, consistent with the view that transient 
activity of these molecules may be beneficial 
for the liver. [16,18,28,31,38,43] 
The first cases of ALPPS occurred in patients 
in Germany where the technique to induce 
accelerated regeneration of the liver was 
discovered by chance [6,7]. By combination of 
portal vein ligation and transection, extensive 
tumor resection was performed and patient 
recovery occurred in record time [44,45,46]. 
The understanding of ALPPS-triggered 
processes is in its infancy; however, 
underlying mechanisms begin to emerge, with 
the JNK1-IHH axis a first example of ALPPS-
specific molecular events that can be 
associated with the unprecedented regenerative 
acceleration. Short-term activation of JNK1 
and IHH might be of use in the clinic. Not 
every patient requiring ALPPS may qualify for 
this major surgery; for example, highly morbid 
patients that may tolerate PVL, but not the 
more invasive ALPPS, may benefit from a 
JNK1-IHH-based promotion of regeneration. 
Although the oncological risks associated with 
long-term activation will not vanish, the 
prevention of imminent death due to liver 
failure may justify the use of compounds 
activating the JNK1-IHH pathway. 
Understanding the extent to which the JNK1 
and IHH signals can be stimulated may open 
the opportunity for pharmacological 
administration to encourage regeneration in at-
risk-patients, eventually expanding the 
boundaries of success in the treatment of liver 
disease one step further.  
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Figures 
 
Figure 1. JNK1 is upregulated early after ALPPS. (A) In-silico analysis linking components of the 
hedgehog pathways to Mapk8 (JNK1) by the String database.  Green lines represent suspected links 
between genes from their database of publications. Blue and pink lines represent experimentally 
determined links between genes. (B) Raw hepatic gene expression values of Mapk8 from RNA 
sequencing data and corresponding qPCR validation.  (C) Hepatic protein expression (normalized to 
GAPDH) of JNK1 and pJNK1 after surgery. N=5/group, t-test, *P<0.05, ** P<0.01. ***P<0.001. 
Significances refer to ALPPS vs. PVL comparison. 
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Figure 2. JNK1/IHH cellular location and associated downstream signaling in liver (A) pJNK1/alpha-
SMA and pJNK1/Ihh immunofluorescence co-stain showing co-localization of both proteins in 
nonparenchymal cells (see Supplementary Figure 1 and 2 for stainings in control surgeries) . (B) 
Cytosolic and nuclear protein levels (normalized to -tubulin and lamin B1, respectively; see 
immunoblots in Supplementary Figure 16) of pJNK1, GLI1, and Cyclin D. (C)  Counts of cyclin D, 
Ki67, and bold pH3-positive hepatocyte nuclei hepatocyte counts(see Supplementary Figure 4 for 
corresponding stains). N=5/group. t-test, *P<0.05,** P<0.01, ***P<0.001. Significances refer to 
ALPPS vs. PVL comparison. 
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Figure 3. JNK1 inhibition reduces the regenerative speed after ALPPS. (A) Cytosolic and nuclear 
pJNK1 levels (normalized to -tubulin and lamin B1, respectively; see Supplementary Fig. 16 for 
immunoblots in). N=5/group. (B) Body weight and liver weight regain (expressed as percent 
FLR/BW) after surgery and treatment with SP600125 are shown in the left and right graph, 
respectively. (C) Corresponding Ki67 and pH3 counts (see Supplementary Fig. 6 for stains). 
N=5/group, t-test, *P<0.05, **P<0.01, ***P<0.001 for ALPPS + DMSO versus ALPPS + SP6 unless 
otherwise indicated.  
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Figure 4. JNK1 inhibition dpwnregulates the IHH pathway after ALPPS. (A) Plasma IHH levels 
(ELISA) and hepatic protein expression (normalized to GAPDH) after surgery and treatment. Hepatic 
gene expression of  (B) Gli1 and (C) Hhip after surgery and treatment. (D) Cytosolic and nuclear 
protein levels (normalized to -tubulin and lamin B1, respectively) of GLI1 and Cyclin D. (E) 
Immunofluorescence for hepatic GLI1. Note that SP600125 treatment reduces nuclear staining in 
hepatocytes. (F) Cyclin D counts (see Supplementary Fig. 9 for stains). N=5/group, t-test, *P<0.05, 
**P<0.01, ***P<0.001 for ALPPS + DMSO vs ALPPS + SP6. 
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Figure 5. Effects of JNK1 inhibition combined with recombinant IHH treatment on regeneration after 
ALPPS. (A) Body weight and liver weight (FLR/BW) after ALPPS+ SP6 with/without  rIHH versus 
corresponding vehicle controls and ALPPS or PVL alone. (B) Corresponding Ki67 and pH3 counts 
(see Supplementary Fig. 10 for stain). N=5/group, t-test, *P<0.05, **P<0.01, ***P<0.001 for ALPPS 
+ SP6 versus ALPPS + SP6 and recombinant Ihh. 
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Figure 6. Effects of JNK1 inhibition combined with recombinant IHH treatment on hedgehog 
signaling after ALPPS. (A) Hepatic gene expression of Gli1 and Hhip after surgery and treatment. (B) 
Cytosolic and nuclear protein levels (normalized to -tubulin and lamin B1, respectively) of GLI1 and 
Cyclin D. (C) Immunofluorescence for hepatic GLI1. Note the restoration of nuclear GLI1 expression 
in SP600125-treated liver through rIHH. (D) Cyclin D nuclear counts see Supplementary Figure 11 for 
stains) (E) Cytosolic and nuclear protein levels of pJNK1. N=5/group,  t-test, *P<0.05, **P<0.01, 
***P<0.001 for ALPPS + SP6 versus ALPPS + SP6 and rIHH. 
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Figure 7. JNK1-IHH signaling from stellate cells as an accelerator of liver regeneration following 
ALPPS surgery. Upon ligation and transection, JNK1 is activated in stellate cells to induce IHH 
secretion. Paracrine activation of the IHH downstream effector GLI1 promotes cyclin D expression in 
hepatocytes, accelerating the cell cycle to enable the regeneration of functional liver remnants as small 
as 10% of the original hepatic volume. IHH further seems to elevate JNK1 activity, suggesting a feed 
forward mechanism that may contribute to the acceleration of regeneration.  
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Supplementary Materials 
 
Supplementary Tables 
Table S1. Taqman gene expression assays 
 
gene name Applied Biosystems order no.  
Gli1 Mm00494654_m1 
Gli2 Mm01293117_m1 
Hhip Mm00469580_m1 
Ptch1 Mm00436026_m1 
Smo Mm01162710_m1 
18S rRNA  Control reagents 
 
 
Table S2. Antibodies 
Antigene Company (order no.) Dilution 
Ki67 Abcam, Cambridge, UK (ab16667) 1:200 (IHC) 
pH3 Millipore, Schaffhausen, CH (06-570) 1:500 (IHC) 
Ihh Abcam, Cambridge, UK (ab39634) 1:500 (IHC) 
Gli1 R&D, Zug, CH (Mab3324) 
1:50 (IF) 
1:5000 (WB) 
Gli2 Abcam, Cambridge, UK (ab26056)  1:500 (WB) 
cyclin D Abcam, Cambridge, UK (ab16663) 
1:100 (IHC) 
1:100 (WB) 
Alpha-SMA Abcam, Cambridge, UK (ab32575) (IF) 
pJNK Santa Cruz, CA USA (sc6254) (IF) 
pJNK R&D, Zug, CH (AF1205) (IHC) 
Ihh Abcam, Cambridge, UK (ab39634) 
(IF) 
(IHC) 
lamin B1 Santa Cruz, CA USA (sc-377001) 1:500 (WB) 
-tubulin Cell Signaling, MA USA (2128S) 1:1000 (WB) 
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Supplementary Figures 
 
Figure S1. Immunohistochemistry for IHH, ASMA, and pJNK1 on liver post surgery. 
 
Supplementary Figure 1. Representative immunostainings for IHH, ASMA, and pJNK1 on liver at 
four hours after ALPPS, PVL, transection, and sham operations. 40x magnification. 
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Figure S2. Immunofluorescent co-stains for pJNK1/ASMA and pJNK1/IHH on liver post 
control surgeries. 
 
Supplementary Figure 2. Representative immunofluorescent co-stains for pJNK1/ASMA and 
pJNK/IHH on liver four hours after PVL, transection, and sham operations. 40x magnification. 
  
 90 
 
Figure S3. JNK1 and GLI2 protein expression in ALPPS versus control surgeries 
 
Supplementary Figure 3. JNK1 and GLI2 cytosolic and nuclear protein levels after ALPPS or its 
surgical controls. N=5 per group. t-test, *P<0.05, **P<0.01. ***P<0.001. Significances refer to 
ALPPS vs. PVL comparison unless otherwise stated.  
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Figure S4. H&E staining and immunohistochemistry for Ki67, pH3, and cyclin D on liver 
post surgery. 
 
Supplementary Figure 4. Representative immunostainings for H&E, Ki67, pH3, and cyclin 1 on liver 
after ALPPS, PVL, transection, and sham operations. Quantitations are shown in Figure 1E. 20x 
magnification. 
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Figure S5. JNK1 nuclear and cytosolic protein levels after JNK inhibition with SP600125. 
 
Supplementary Figure 5. JNK1 nuclear and cytosolic protein levels determined by western blot in 
ALPPS livers with control injection (DMSO) or SP600125. N=5 per group. No significant differences 
between ALPPS+DMSO and ALPPS+SP6 group comparisons. 
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Figure S6. Immunohistochemistry for H&E, Ki67, and pH3 on liver after JNK1 inhibition by 
SP6. 
 
Supplementary Figure 6. Representative immunostainings for H&E, KI67, and pH3 on liver after 
treatment of ALPPS mice with DMSO, vehicle, or SP600125. 20x magnification. 
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Figure S7. mRNA analysis of Smo, Ptch1, Gli2, and Hhip in livers with JNK1 inhibition by 
SP6. 
 
Supplementary Figure 7. mRNA expression analysis of downstream components of IHH signaling in 
livers with JNK1 inhibition. N=5 per group. No significant differences between ALPPS+DMSO and 
ALPPS+SP6 group comparison.  
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Figure S8. GLI2 protein levels in livers with JNK1 inhibition by SP6.  
 
Supplementary Figure 8. Hepatic GLI2 protein levels in nuclear and cytosolic fractions after vehicle 
(DMSO) or SP600125 treatment followed by ALPPS. N=5 per group. No significant differences 
between ALPPS+DMSO and ALPPS+SP6 group comparison.  
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Figure S9. Immunohistochemistry for cyclin D1 on liver after JNK1 inhibition by SP6. 
 
Supplementary Figure 9. Representative immunostainings for pJNK and cyclin D on liver after 
treatment of ALPPS mice with DMSO vehicle or SP600125. 20x magnification.  
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Figure S10. Immunohistochemistry for H&E, Ki67, and pH3 on livers with JNK1 inhibition 
by SP6 and recombinant IHH treatment.  
 
Supplementary Figure 10. Representative immunostainings for H&E, KI67, and pH3 on liver after 
treatment of ALPPS mice with vehicle injections (DMSO and PBS), or SP600125, or SP600124 and 
recombinant IHH injections. 20x magnification. 
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Figure S11. Immunohistochemistry for cyclin D on liver after JNK1 inhibition and 
recombinant IHH treatment. 
 
Supplementary Figure 11. Representative immunostainings for pJNK and cyclin D1 on liver after 
treatment of ALPPS mice with vehicle (DMSO and PBS), or SP600125, or SP600125 and 
recombinant IHH treatment. 20x magnification. 
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Figure S12. mRNA analysis of Ptch1, Smo, Gli2, and Hhip in livers with JNK1 inhibition 
and recombinant IHH treatment.  
 
Supplementary Figure 12. mRNA expression analysis of downstream components of IHH signaling 
in livers with JNK inhibition and recombinant IHH treatment. N=5 per group. t-test, *P < 0.05, **P < 
0.01. ***P < 0.001. Significances refer to ALPPS+SP6 vs. ALPPS+SP6+rIHH comparison.  
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Figure S13. GLI2 protein levels in livers with JNK1 inhibition and recombinant IHH 
treatment.  
 
Supplementary Figure 13. GLI2 protein levels in nuclear and cytosolic fractions in livers with 
vehicle (DMSO&PBS), or SP600125, or SP600125 and recombinant IHH treatment. N=5 per group. t-
test, *P < 0.05, **P < 0.01. ***P < 0.001. Significances refer to ALPPS+SP6 vs. ALPPS+SP6+rIHH 
comparison.  
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Figure S14. JNK1 protein levels in livers after JNK loss treatment and recombinant Ihh 
treatment. 
 
Supplementary Figure 14. JNK1 protein levels in nuclear and cytosolic fractions in livers of ALPPS 
mice treated with vehicle injection (DMSO & PBS), or SP600125, or SP600125 and recombinant IHH 
(referring to Figure 6E). N=5 per group. t-test, *P < 0.05, **P < 0.01. ***P < 0.001. Significances 
refer to ALPPS+SP6 vs. ALPPS+SP6+rIHH comparison.   
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Figure S15. Immunohistochemistry for pJNK1 on liver after JNK1 inhibition and 
recombinant IHH treatment. 
 
Supplementary Figure 15. Representative immunostainings for pJNK1 on liver after treatment of 
ALPPS mice with vehicle (DMSO and PBS), or SP600125, or SP600125 and recombinant IHH 
treatment. 20x magnification. Note the moderate re-elevation in pJNK1 nuclear expression in 
SP600125-rIHH-treated liver, consistent with a positive feedback between IHH and JNK1. 
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6. Discussion 
The development of ALPPS surgery has pushed the limits of resectability in liver surgery 
and has introduced a novel management of severe liver malignancy. The innovation of 
ALPPS illustrates that a conceptually simple combination of existing surgical techniques can 
unleash regenerative responses that are beyond our expectations. ALPPS demonstrates that 
the intrinsic capacity of the liver to regenerate is larger than previously thought, yet is usually 
confined. The unprecedented effect of ALPPS on liver recovery has provoked strong interest 
in the mechanisms that account for this acceleration of liver regeneration. 
 Mechanistically, liver regeneration after simple sHx is highly complex [8]. 
Furthermore, how contralateral liver growth after simple portal vein ligation (PVL) occurs is 
ill-understood [103]. More so, how regeneration is then accelerated by parenchymal 
transection is completely unknown. The observation that plasma obtained from ALPPS mice 
can mediate this acceleration [76] in PVL mice pointed to circulating molecules as mediators 
of the ALPPS effects, perhaps reflecting the outcomes of an injury response.  
 During these past few years of my PhD, my aim was to elucidate unique pathways 
underlying ALPPS using different Omics approaches. I used (i) genomics to explore the 
pathways dysregulated after ALPPS relative to surgical controls, and (ii) proteomics 
approaches on ALPPS plasma to identify the circulating factors that mediate the regenerative 
effects. In brief, my research revealed the following undescribed interaction between JNK1 
and IHH in stellate cells as an early instigation of accelerated liver regeneration after ALPPS 
stage 1 surgery: 
a) IHH and JNK1 reside in stellate cells and activation of each is associated with liver 
weight gain, while the peak in JNK1 precedes the upregulation of IHH, which 
precedes the activation of its downstream targets GLI1 and cyclin D1 in 
hepatocytes. 
b) Individual partial inhibition of IHH and JNK1 reduced the rate of regeneration to 
that seen after PVL alone, along with congruent decreases in the IHH-GLI1-cyclin 
D1 axis and in hepatocellular proliferation. 
c) Recombinant IHH is sufficient to restore ALPPS regeneration in PVL mice and in 
JNK1-inhibited mice, providing evidence that JNK1 accelerates regeneration 
through IHH. 
In brief, we report the first insights into the molecular principles underlying the acceleration 
of liver regeneration through ALPPS surgery. 
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6.1 The role of the JNK1-IHH-Cyclin D-axis  
 The role of JNK1 in regeneration and other liver diseases is being discussed in 
Manuscript B, while the regenerative role of IHH has already been addressed in Manuscript 
A. However, the link between JNK1 and the described IHH-GLI1-cyclin D axis has not been 
reported in any other regenerative model. In regeneration after sHx, JNK1 is upregulated at 1 
hour [92,96,104], similarly to ALPPS. Unlike the 4 hours after ALPPS, however, Ihh mRNA 
peaks at 48 after sHx [78,85] and is not upregulated at early timepoints (Fig 11), suggesting 
no comprehensible link between these two molecules exists in a normal regenerating liver. 
Further experiments including the inhibition of JNK and the concomitant analysis of the 
hedgehog pathway before and at 48 hours would need evaluation to determine whether 
regulation of IHH through JNK1 indeed is unique to ALPPS. Schwabe et al used SP600125 to 
inhibit JNK after sHx, but only illustrated the decrease of proliferation along with cyclin D1 
downregulation at 24h after sHx [96]. On the other hand, we observed a modest elevation of 
SHH at 4 hours after sHx relative to ALPPS and sham (Supplementary Fig. 4, manuscript A), 
implying JNK1 may regulate SHH rather than IHH after sHx provided JNK-hedgehog 
interactions exist after normal resection.  
 
 
 
 
 
Figure 11. IHH is not upregulated after sHx in plasma at early time points after surgery, compared to 
ALPPS. 
Furthermore, investigating potential upstream regulators of JNK, such as MKK4 and 
MKK7, may further elucidate the mechanistic differences of JNK1 in sHx versus ALPPS. 
Wuestefeld et al show that MKK4 silencing increased the regenerative capacity of hepatocytes 
in models of liver regeneration [105]. Puzzlingly, our preliminary experiments showed a 
potential increase in pMKK4 expression at one hour after ALPPS (but not on the mRNA 
level, Fig 12), suggesting early activation rather than silencing. A detailed analysis of the 
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MAPK cascade early after ALPPS and sHx will be needed to reveal any contributions of 
MKKs to accelerated regeneration.   
 
 
 
 
 
 
Figure 12. Evaluation of MKK4 in ALPPS. (A) pMKK4 may be upregulated on the protein level in 
ALPPS TIME, however (B) no differences are observed at the MRNA expression levels.  
An important aspect concerns the potential role of the JNK1-IHH-cyclin D axis in 
tumor biology. Ideally, stimulating this mechanism in a small, timely limited dose would 
instigate a signal large enough to induce regeneration in an otherwise incapable organ, but 
small enough to avoid the promotion of cancer or other disease (in the case of fibrosis and 
NASH). As far as we understand from pilot experiments and human ALPPS registry data, 
ALPPS does not induce further tumor progression [Patryk Kambakamba, unpublished] 
allowing us to hypothesize that in the right conditions, the JNK1-IHH-cyclin D-axis could be 
manipulated in a controlled way as to promote regeneration without further effects.  
 
6.2 Limits to proteomics 
The main techniques in the explorative approach to screen for potential mechanisms 
behind ALPPS regeneration relied on large data sets obtained from genomics and proteomics. 
The two publications listed in this thesis resulted from extensive analysis of the gene 
expression data incurred by RNA deep sequencing. However, Schlegel et al demonstrated that 
ALPPS plasma harvested 30 minutes after operation was sufficient to propagate accelerated 
regeneration when injected into PVL mice. In an effort to identify the kind of plasma 
molecules contributing to these effects, I depleted and concentrated the plasma proteins into 
two fractions (one with 95% protein depletion, the other with 95% protein concentration). 
Only the protein-concentrated fraction elicited the ALPPS regenerative response (and the 
protein-depleted fraction prompted a PVL-like regenerative response, Fig 13), identifying 
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proteins as the likely accelerators. Therefore, proteomics approaches were coveted to identify 
the circulating proteins involved in ALPPS regeneration - particularly because identifying 
such proteins would have direct clinical relevance.  
 
 
 
 
 
 
Figure 13. ALPPS plasma protein depletion and concentration using the BindPro Metabolomics Kit 
(Biotech Support Group, New Jersey USA). 
 
However, the proteomics approach sustained many challenges that inhibited the 
completion of some of our aims within this project. For one, proteomics profiling on 
regenerative tissue after sHx is variable and not very well defined [106]. Secondly, we 
conducted proteomics research on plasma samples from ALPPS mice and their appropriate 
controls 30 minutes after operation. This alone presents many obstacles, as proteomics is not a 
very well established technique on the complex sample content that is plasma [107,108]. One 
huge trial is the fact that approximately 52% of the proteins in plasma are albumin, making it 
very difficult to identify other small proteins because they are ‘blocked’ by the abundance of 
albumin, or are bound to albumin and cannot be distinguished separately [109,110]. 
Regardless of this obstacle, I attempted several protocols to generate the most easily 
identifiable proteins in our plasma samples. Using a discovering approach (shotgun 
proteomics), I began with trypsin digestion and mass spectrometry (MS) on whole plasma. 
With this method, the MS instrument runs in data-dependent acquisition (DDA) mode 
generating fragment ion spectra for selected precursor ions detectable in a survey scan. The 
fragment ion spectra are then assigned to their corresponding peptide sequences by sequence 
database searching. This method led to the identification of only <1000 plasma proteins. To 
increase the protein detection number, I depleted the top 7 abundant proteins (Seppro Mouse 
Spin Columns, Sigma-Aldrich, Germany) from whole plasma before trypsin digestion and 
MS. However, after many trials, our Mascot search and Spectronaut analysis (peptide 
sequence databases to identify proteins) did not yield an increase in the detection number. As 
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a final push in obtaining optimal proteomics data, we utilized a new technique described as 
Swath MS/MS [111]. This method uses a new strategy labeled data-independent acquisition 
(DIA). Using a cyclic recording (the MS steps within 2-4 seconds cycle time) through a set of 
consecutive survey scans (with acquisition windows designed to cover 400-1200 m/z), the 
whole peptide mass range is readily covered by the mass analyzer in a time frame where most 
of the tryptic peptide precursors of the organism are present [112,113]. This technique evades 
the low sensitivity and propagation of errors normally attained with DDA and allows for a 
more in-depth identification of peptides present in a protein sample. Using whole plasma, 
target spectrum library assays were generated using DDA experiment on a Q-Exactive HF 
instrument. Data were searched with Mascot v2.4 and search results were further processed 
using the Bioc R package specL. DDA and DIA were acquired back-to-back in a randomized 
order on the MS for full peptide identification coverage. This sample preparation method and 
analysis allowed for the identification of over 4700 proteins, giving us the largest chance in 
identifying plasma proteins unique to ALPPS. As the sham operated group were distinct in 
their clustering from the other operated groups (PVL, transection, and ALPPS), the sham 
group was excluded from analysis for the identification of dysregulated proteins in ALPPS 
plasma.  
One further observation that adds to the limitations of these results is that all ALPPS 
samples had a good correlation (pearson correlation above 0.9); however the PVL and 
transection groups had correlation scores below 0.8, suggesting a ‘batch effect’ in the sample 
preparation process (although I tried to prevent this as much as possible with mice from the 
same cage, operated at the same time, etc). This higher-than-expected variability could affect 
the analysis of proteins that are differentially expressed. As a result of these limitations, the 
top dysregulated proteins were still very difficult to validate on the protein level in plasma, 
marking this section of my PhD thesis as incomplete. Further details of the proteomics results 
are described below in Future Directions.  
 
6.3 Regeneration and wound healing 
 It is very well known that the mechanisms of regeneration and wound healing are 
intermixed. After all, regeneration is a repair mechanism in response to liver tissue loss. 
Wound healing is categorized into three consecutive, yet overlying phases (akin to 
regeneration, see section 3.2) that occur in parallel with the initial response of hemostasis: 
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inflammation, proliferation, and remodeling [114,115]. Mechanisms similar between organ 
regeneration and wound healing include the increase of inflammation, in particular 
macrophage/Kupffer cell activation, blood clots, fibroblast migration, MMP upregulation, 
ECM reorganization, wound epithelium formation, and angiogenesis. However, processes 
unique to regeneration include those associated with new growth to completely restore 
portions of damaged tissue to its normal state. Meanwhile, severely damaged or non-
regenerative tissue may be replaced with collagen deposits and fibrosis, often leading to an 
end point of scarring, and are processes unique to wound healing [116,117]. As there are 
many types of injury leading to wound healing processes, we will focus on repair mechanisms 
in cutaneous wounds. 
Hedgehog in wound healing 
Wounding triggers a cascade of signaling events to ensure a normal re-
epithelialization. Although the hedgehog pathway’s involvement during development has 
been extensively studied, much less is known about its role in wound repair. Recently, an 
increasing number of studies evaluated the effect of sonic hedgehog (SHH) on dermal repair 
and wound vascularization [118]. Interestingly, diabetic mice treated with topical application 
of human SHH-expressing plasmids exhibited improvements in re-epithelialization and 
dermal healing [119]. On the other hand, mice treated with the SHH inhibitor cyclopamine 
after wounding showed delayed wound closure and reduced dermal granulation tissue 
formation [120]. Therefore, the hedgehog pathway has the potential to influence several 
aspects of wound healing, including dermal repair and vascularization. This further suggests 
parallels between wound healing and liver regeneration, albeit the specific roles of SHH and 
IHH in cutaneous wound healing need to be further defined. 
JNK in wound healing  
 JNK signaling has also been shown to be critical to the cascade of events in wound 
healing. For example, inhibition of JNK impairs keratinocyte migration and the healing of an 
in vitro wound, while maintaining keratinocyte differentitation [121]. Furthermore, mice 
deficient in MEKK1, an upstream kinase of JNK, exhibit a significant healing delay due to 
impaired activation of JNK and reduced expression of genes involved in ECM homeostasis 
[122]. Although the specific role of each JNK isoform has not been addressed in many of 
these studies, a combinatory redundant role between JNK1 and JNK2 appears plausible. 
JNK1 has been the most implicated in liver regeneration; nevertheless, the role of JNK2 is not 
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discounted as conflicting publications show divergent roles for JNK2. Sabapathy et al 
indicated that the loss of JNK2 accelerated liver regeneration [95], while Das et al illustrated 
that JNK2 has no role in liver regeneration [102]. Defining the time course of activities for 
each JNK gene could help pinpoint the true differences or parallels between organ 
regeneration and cutaneous wound healing. 
Inflammation in wound healing 
 The inflammatory phase is well-characterized in cutaneous wound healing and 
therefore is of relevance for accelerated regeneration after ALPPS. The inflammatory 
response is characterized by an influx of immune cells in response to damage-associated 
molecular patterns (DAMPs), where leukocytes enter the wound area while chemoattractants 
recruit neutrophils. Later on (48 hours after the lesion), monocytes infiltrate the area and are 
differentiated into macrophages, which release growth factors (i.e. PDGF and VEGF) 
necessary for triggering and propagating new tissue in the lesion area [123]. Importantly, the 
activation of these cells is eventually settled by the reorganization of the ECM the newly 
formed blood vessels [115]. Tissue regeneration is in part promoted by the early acting 
leukocytes that interact with tissue scaffolds, while in wound healing lymphocytes foster 
chronic inflammation and favor scarring over regeneration. Furthermore, the identification of 
CD4+ T cells role in terminating inflammatory responses could be important in propagating 
regeneration over chronic inflammation and scarring [124,125]. Therefore, in both 
regeneration and wound healing, the inflammatory response is essential in initiating, 
mitigating, and terminating the injury. However, regeneration will occur not only if the 
injured cells are capable of proliferation but also only if the underlying stromal framework is 
intact. If injury is so severe that there is damage to the stromal framework of the tissue, 
regeneration will not occur [117]. 
 Lastly, an important component to take into account for all repair mechanisms are the 
circulating factors such as cytokines, immune cells, and other mitogens. Many of these factors 
have been identified in both wound healing and regeneration (IL-6, TGF-beta, FGF, etc); 
nevertheless, parallel profiling should be conducted to ascertain new molecules specific to 
each process. This comparison could either lead to identification of unknown pathways in 
these injury responses, or identify unique pathways to each, distinguishing differences 
between regeneration and wound healing. Furthermore, understanding the full extent of these 
circulating factors could also help extend knowledge to wound healing occurring in diseased 
tissues, perhaps in cases where repair would not occur successfully because the repair 
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mechanisms have already been activated to an extent where healing is faulty and is rather 
incurring further damage. 
Altogether, it appears that many similarities exist between ALPPS, regeneration, and 
wound healing. JNK and hedgehog pathways are known to partake in all three cases; 
however, at different timepoints, in varied combinations, and possibly propagating different 
downstream targets. Therefore, exploring the timing, involvement of other ligands, and 
interactions with different molecules could characterize the quality and outcome of an injury 
response.  
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7. Future Directions 
JNK2 as a player in the IHH-cyclin D axis 
In the above manuscripts, we demonstrated that the JNK1-IHH-Cyclin D axis is a 
necessary component to induce accelerated liver regeneration after ALPPS surgery. However, 
as the roles of IHH after sHx is not definitive, neither is the role of JNK2. Although JNK1 is 
upregulated 1 hour after sHx, it seems unlikely to have the same interacting role with the 
hedgehog pathway as we have shown in ALPPS, as hedhehog signaling appears to occur with 
a significant delay (24-48h) after sHx [85] compared to ALPPS (4h). Therefore, JNK2 night 
play this role in regeneration after sHx (with JNK3 being expressed only in neuronal cells 
[92,126]) (Fig 14). Likewise, the role of the other hedgehog ligands (SHH, DHH) and their 
association with JNKs remains uncharacterized after sHx. Therefore, it could be viable that 
JNK2, rather than JNK1, is interacting with the hedgehog pathway, perhaps through a ligand 
different than IHH.  
 
 
 
 
 
 
 
 
 
 
Plasma factors upstream of the JNK-IHH-cyclin D axis 
As described above, we conducted proteomics analysis on plasma samples from mice 
30 minutes after ALPPS and control surgeries to connect early circulating factors to the 1h 
upregulation of JNK1 that mediates the secretion of IHH at 4 hours after operation. Despite 
the technical challenges of plasma proteomics, ANOVA analysis presented GSTP1 
(glutathione s-transeferase pi 1), GPDA (glyceraldehyde-3-phosphate dehydrogenase), and 
HS90A (heat shock protein 90) as the three most significant plasma proteins present 30 min. 
after ALPPS compared to PVL and transection (Fig 15).   We focused on validating GSTP1 in 
mouse, known not only for its detoxification properties but also for its phosphorylation 
Figure 14. Mapk8 (JNK1), Mapk9 (JNK2), Mapk10 (JNK3) gene expression values from RNA deep 
sequencing. Although JNK2 seems not be be expressed in ALPPS, whereby JNK1 is highly upregulated, 
JNK2 could play a compensatory role in regeneration after sHx in interacting with the IHH-CCND1 
axis.  
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activites on MAPKinases in a catalytic-independent manner [127]. Moreover, GSTP1/2 
knockout mice display reduced proliferation and delayed activation of STAT3, JNK, and 
ERK1/2 signaling after sHx [127]. Validation of GSTP1 upregulation would hence make 
GSTP1 a promising upstream regulator of JNK1 (upregulated in tissue at 1 hour).  
 
 
 
 
 
 
 
 
Indeed, serum GSTP1 (measured by ELISA) was upregulated after ALPPS, however 
at a time point later than 30 minutes post ALPPS (Fig 16). Therefore, the ELISA 
measurements could not corroborate the proteomics findings, rendering a regulation of JNK1 
through GSTP1 unlikely. Functional evidence (i.e. GSTP1 inhibited by NBDHEX with 
JNK1-IHH-GLI1-cyclin D assessment) would eventually be required to establish the precise 
relationship between GSTP1 and JNK1-depedent regeneration after ALPPS. 
 
 
 
 
 
 
 
 
In an alternative appraoch to shed light onto GSTP1, we measured protein levels in 
human ALPPS patient plasma (Figure 17). Human plasma was obtained prior to surgery, at 
laparotomy, and at several time points after both ALPPS stage 1 and 2 surgery. Unfortunately, 
Figure 15. The top 3 dysregulated plasma proteins identified by DIA using MS and ANOVA. 
GSTP1, GPDA, HS90A.    
Figure 16. mRNA and protein levels of GSTP1 in mouse suggesting a role of GSTP1 as a plasma 
factor induced by ALPPS. 0.5 hour time point, student’s t-test, PVL compared to ALPPS, (A) 
p=0.35, (B) p=0.03, (C) p=0.0001. 
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only one out of 10 patients had elevated GSTP1 plasma levels. More so, this patient was the 
only one displaying a decrease in the FLR percentage after stage 1 (i.e a negative regeneration 
rate after operation). Therefore, we decided not to follow up GSTP1 as a feasible candidate 
promoting the JNK1-IHH axis. However, our findings do not rule out a role for GSTP1 in 
ALPPS regeneration and further work may re-integrate GSTP1 as an important player. A 
wider array (and more complete set) of samples from a well characterized and more 
homogenous ALPPS patient cohort may be needed to appreciate a regenerative function of 
GSTP1. Likewise, a more dense time course assessment in mice and man may be of help 
given that the regenerative kinetics after ALPPS are different in the two species. 
 
 
 
 
 
 
 
 
 
 
Lastly, as a supplement to our proteomics approach, we conducted plasma protein 
microarrays (Mouse L308 Array, RayBiotech) on ALPPS, PVL, and transection mouse 
samples (Fig 18). The plasma protein microarray did reveal unique differences between 
ALPPS and the control surgeries, particularly the spots for DTK, Frizzled-7, and RANTES 
seemed to be upregulated. If validated by ELISA or other techniques, these candidates may be 
investigated through functional approaches in future studies. 
 
 
 
 
Figure 17. Protein levels of GSTP1 in 
human ALPPS patient plasma. Patient 
11 is the only sample with a decrease 
in the percentage FLR after stage 1 
corresponding with the large increase 
in GSTP1 protein levels in plasma.  
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Characterization of ALPPS processes in mice 
 The molecular mechanisms in our ALPPS mouse model need to be further 
characterized to understand the full extent of the processes induced by accelerated 
regeneration. Firstly, the time course for cell cycle transitions (G0 to G1 to S to M phase) in 
ALPPS should be explored. Using the genomics data from this project as well as other 
genomics data accumulated in our lab (for sHx), the time adapted phases should be compared 
between ALPPS, PVL, and sHx to identify, for example, whether regeneration after ALPPS 
follows the same basic principles as after sHx, however in a timely condensed way.  
Secondly, the JNK1-IHH positive feedback loop needs further investigation to confirm 
such relation between these two molecules. We have done a few preliminary experiments 
with neutralizing IHH antibody to see whether IHH inhibition may reduce JNK1 activity after 
ALPPS; however, our results did not show a direct effect of neutralizing IHH on JNK1 (Fig 
19). These experiments need repetition, perhaps with a more direct inhibition of IHH such as 
through a hepatocyte-specific knockout mouse model or via siRNA. Likewise, hepatic stellate 
cell culture experiments may be helpful for mechanistic studies on the kind of interaction 
between IHH and JNK1.  
Figure 18. Mouse L308 Array screens 308 mouse proteins with high detection sensitivity.  
PVL Transection ALPPS 
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Pathway analysis in ALPPS patients 
Lastly, to further corroborate the results of our ALPPS mouse model in clinical settings, 
we have conducted RNA deep sequencing on human ALPPS tissue (Fig 20). Due to ethical 
constraints, liver biopsies could only be collected after laparotomy (before ALPPS), and 
before surgical closure (after complete ALPPS stage 1). We isolated RNA from 5 patient 
biopsies with similar disease background, positive regenerative rates after ALPPS, and short 
interval times between stage 1 and stage 2 of ALPPS. From our preliminary analysis, we see a 
complete gene expression profile shift in biopsies after ALPPS surgery. Our aim is to identify 
the common pathways and genes dysregulated in ALPPS between these patient biopsies and 
our published mouse data series (manuscript A), should they exist.  Therefore, validation of 
JNK1 and additional confirmation of IHH is priority. This comparison would solidify the 
clinical relevance of our ALPPS mouse model. More so, it might promote the view of the 
JNK1-IHH axis as a possible therapeutic target for patients at risk of liver failure due to 
incompetent regeneration after surgery.  
 
Figure 19. (A) Nuclear pJNK1 and (B) JNK1 fractions in mice that underwent neutralizing IHH 
antibody (aIHH) before AL PS surgery. 
(A) (B) 
Figure 20. RNA deep sequencing 
on human ALPPS regenerative 
liver tissue. ‘1L’ samples denote 
before surgery, while ‘3L’ samples 
correspond to after ALPPS stage 1 
surgery. 
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